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ABSTRACT 
Large granular lymphocytic (LGL) leukemia is a chronic incurable disorder 
characterized by expansion of cytotoxic T- or natural killer (NK)-lymphocytes 
infiltrating blood and bone marrow. The diagnostic criteria include persistent 
lymphocytosis in peripheral blood, and in the case of T-LGL leukemia, detection of a 
clonal rearrangement of the T cell receptor. Typical clinical and hematological 
characteristics, including anemia, neutropenia, and autoimmune disorders, further 
support the diagnosis. Current immunosuppressive treatment options, such as 
methotrexate, induce remission in only 50% of cases and no targeted therapies exist. 
The aim of this project was to characterize the molecular pathogenesis of LGL 
leukemia and find molecular markers that could be used for diagnosis and novel 
therapeutic approaches. 
In the first study, the molecular background of LGL leukemia was analyzed by 
exome sequencing of a T-LGL leukemia patient. The index patient carried a novel 
D661V mutation in the Signal transducer and activator of transcription 3 (STAT3) 
gene. STAT3 is a known oncoprotein and a transcription factor. In the subsequent 
screening, the prevalence of somatic STAT3 mutations in T-LGL cases was 40%. 
Based on functional studies, the mutations located in the SRC-like homology 2 (SH2) 
domain increased phosphorylation and transcriptional activity of STAT3.  
A larger LGL-leukemia patient cohort, including both T-LGL leukemia and 
chronic lymphoproliferative disorder of NK cells (CLPD-NK) patients, was analyzed 
in the second study. Activating STAT3 mutations were seen in 27% and 30% of cases, 
respectively. The analysis of clinical characteristics showed that patients with STAT3 
mutations were more likely to have neutropenia and rheumatoid arthritis and also 
required more frequent treatment when compared with unmutated patients.  
The third study concentrated on the analysis of STAT3 mutation-negative patients 
by exome sequencing. Two T-LGL leukemia patients carried Y665F mutation in 
STAT5B gene. In the screening of over 200 T-LGL leukemia and CLPD-NK cases, 
two patients presented with additional N642H mutation in STAT5B. The mutations 
were situated in the SH2 domain and led to increased phosphorylation and 
transcriptional activity of STAT5B. The in vitro effects of N642H mutation were 
more prominent, and both patients harboring N642H mutation had an untypically 
aggressive clinical presentation.  
In the fourth study, the clonal hierarchy and STAT3 mutation spectrum during 
immunosuppressive treatment was analyzed by deep amplicon-sequencing of STAT3 
and simultaneous deep sequencing analysis of a T cell receptor beta chain (TCRB) 
repertoire. A total of 22% of STAT3-mutated patients harbored multiple STAT3 
mutations mostly in separate lymphocyte clones. Mutated clones did not share 
common T cell receptor beta chain (TCRB) sequences by deep sequencing method in 
three T-LGL leukemia cases analyzed. Complete remission after immunosuppressive 
therapy resulted in the eradication of the STAT3-mutated clone in most patients, 
whereas partial responses reflected only modest changes in the leukemic clone 
burden. 
In conclusion, the activating STAT3 and STAT5B mutations provide a basis for 
understanding the molecular pathogenesis of leukemic LGL expansion. LGL 
leukemia can result from chronic antigen exposure in combination with 
immunogenetic factors such as STAT mutations. The detection of STAT3 and STAT5B 
mutations can be included in the diagnostic criteria of LGL leukemia, and facilitate 
development of novel therapeutics. 
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INTRODUCTION 
Large granular lymphocytic (LGL) leukemia was first described in the literature in 
the 1980s, but the ultimate factors driving leukemic expansion remain unknown 
despite several studies that have noted marked disturbances in the cytokine profiles of 
LGL leukemia patients and dysregulated immune system.1-3 Consequently, 
therapeutic approaches have focused on the use of non-targeted immunosuppressive 
drugs, but these have proved to be ineffective in most patients and have marked side 
effects in long-term use. 
Leukemic T-large granular lymphocytes (T-LGLs) are terminally differentiated 
effector memory cells that have encountered their antigen. Phenotypically similar but 
transient lymphocytosis is often seen during viral infections or autoimmune diseases. 
In these disorders, expanded lymphocytes undergo programmed apoptosis by 
activation-induced cell death (AICD). Based on previous studies, LGL leukemia cells 
are resistant to Fas cell surface death receptor (FAS)-mediated AICD. Several anti-
apoptotic pathways are active in LGL leukemia, the most important being interleukin-
6 (IL-6)-Janus kinase (JAK)-Signal transducer and activator of transcription 3 
(STAT3) pathway, which controls the transcription of different proteins that are 
connected to cell cycle control and proliferation. STAT3 inhibition restores the FAS-
sensitivity of leukemic LGLs.4 STAT3 is a pleiotropic transcription factor and an 
oncogene, and its activation has been described in multiple malignancies as an 
important secondary event caused by activation of cancer-specific oncoproteins. 
Chromosomal aberrations are extremely uncommon in LGL leukemia and disease-
specific genetic changes have not been observed. In recent years, the rapid 
development of novel sequencing methods has enabled fast and relatively cheap 
analysis of somatic genetic variants in different cancers. These methods could be used 
to sequence the exome or genome of leukemic LGLs using tumor cell populations and 
their normal counterparts, which can be collected and sorted from the bloodstream.  
The diagnosis of LGL leukemia often requires follow-up and no specific 
molecular markers exist. The analysis of T-cell receptor (TCR) rearrangement in T-
LGL leukemia proves the clonality of lymphocyte expansion, but clonal cells are a 
normal physiological phenomenon after antigen-exposure and thus are seen also in 
non-malignant conditions. Similar methods are not available for the analysis of 
clonality in chronic lymphoproliferative disorder of NK cells (CLPD-NK). In many 
malignancies, specific molecular markers are used in diagnostics and they also 
represent a subject for targeted therapy: for example, chronic myeloid leukemia 
(CML) is characterized by the Breakpoint cluster region (BCR)-Abelson murine 
leukemia viral oncogene homolog 1 (ABL1) fusion gene, which is targeted by 
tyrosine kinase inhibitors. Indeed, modern rational drug design is based on the 
hypothesis that a disease has a specific molecular abnormality, which can be 
addressed with targeted therapy.  
The aim of this study was to characterize the molecular pathogenesis of LGL 
leukemia using second-generation sequencing methods. In addition, the clonal 
hierarchy of leukemic cells was analyzed in detail using flow cytometry-based sorting 
and deep targeted sequencing.  
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REVIEW OF THE LITERATURE 
1. History of LGL leukemia 
Large granular lymphocytes (LGL) belong to the lymphoid lineage of 
hematopoietic cells and are morphologically recognized as mature lymphocytes by 
mononuclear cell type and azurophilic granules (Figure 1).5 Several diseases are 
caused by LGLs; for example, a report of patients with neutropenia and increased 
number of circulating LGLs was published in 1977.6 Thomas P. Loughran and 
colleagues demonstrated the proof of clonality in 1985, based on the detection of 
clonal cytogenetic abnormalities in two patients with increased numbers of LGLs and 
chronic neutropenia.1 The clonal cells were able to infiltrate different tissues, so the 
disease entity was named LGL leukemia and the term is still used.1 In its history, the 
disease was also called various names such as T cell chronic lymphocytic leukemia 
(CLL), lymphoproliferative disorder of granular lymphocytes, or Tγ lymphocytosis.7 
The FAB classification in 1990 established LGL leukemia as the preferred term and 
in 1993, a distinction was made between T-LGL and natural killer (NK) cell LGL 
leukemia.7,8 In the latest World Health Organization (WHO) 2008 classification, NK-
LGL leukemia was further divided into two subcategories: chronic 
lymphoproliferative disorder of NK-cells (CLPD-NK) and rare aggressive NK-LGL 
leukemia.9 In the following text, the term LGL leukemia includes both T-LGL 
leukemia and CLPD-NK. 
 
 
Figure 1. MGG staining of a large granular lymphocyte in peripheral blood. 
Courtesy of Kirsi Latvala. 
 
2. Clinical characteristics and diagnosis of LGL leukemia 
2.1. Common features of T-LGL leukemia and CLPD-NK 
The diagnosis of T-LGL leukemia and CLPD-NK is based on persistent (lasting 
over six months) peripheral blood (PB) lymphocytosis with expression of 
characteristic immunophenotype, positive clonality testing (in case of T-LGL 
leukemia), and typical clinical presentation (Table 1).3,9  
The cells have a distinct morphology: large size (15-18 µm), abundant cytoplasm 
with a variable number of azurophilic granules and a relatively round nucleus with 
condensed chromatin (Figure 1).10 The normal LGL count in PB is 0.2-0.4 x109/l, 
while in LGL leukemia patients it is usually over 2 x109//l, although the diagnosis can 
be established with lower values (>0.5 x109//l) if other diagnostic criteria are 
met.2,11,12 LGLs comprise 5% to 15% of peripheral blood mononuclear cells in normal 
individuals. They mediate direct cytotoxic activity and can be divided into two 
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subsets based on CD3 expression on their surface: CD3neg NK cells and CD3+ T 
cells.13 Some patients have both T and NK cell expansions.14 The number of bone 
marrow (BM) infiltrating lymphocytes varies in LGL leukemia, and the LGLs 
resemble morphologically granulocytic or monocytic precursor cells, making it 
difficult to distinguish them without immunohistochemical staining.10 LGLs can 
infiltrate the red pulp of the spleen, causing mild or moderate splenomegaly, but 
lymphadenopathy is rare.10 Involvement of the liver is also common, although rarely 
examined by histological samples. 10  
In addition to persistent lymphocytosis and morphological analysis, the diagnosis 
of LGL leukemia requires usually immunophenotypic examination and clonality 
testing, and is further supported by typical hematological and autoimmune 
manifestations. 
 
2.2. Laboratory diagnostics of T-LGL leukemia 
Morphological analysis alone cannot separate leukemic LGLs from their normal 
counterparts, but the phenotype of the cells is almost always aberrant.15 Modern 
laboratories analyze the surface marker expression by flow cytometry. Leukemic 
LGLs in T-LGL leukemia are mature postthymic lymphocytes. The phenotype of the 
cells is usually CD3+ T-cell receptor (TCR)-α/β+ CD4neg CD8+ CD5dim CD16+ 
CD27neg CD28neg CD57+ CD62Lneg, which defines them as activated effector 
lymphocytes (Table 1).10 The expression of common T-cell antigens such as CD5 and 
CD7 is often lost or diminished.15 The CD8+ TCR- α/β+ phenotype comprises over 
90% of cases, whereas CD4+ or TCR-γ/δ+ LGL leukemia is rare.7,16 CD57 and CD16 
are commonly NK cell antigens, but their aberrant expression is typical for T-LGL 
leukemia.7 Based on the expression of CD45RA, and the lack of CD62L and 
chemokine-receptor 7 (CCR7) expression, leukemic LGLs have the phenotype of 
terminal-effector memory cells.17,18 Expression of CD56 in T-LGL is connected to 
atypical aggressive T-LGL leukemia.19 
The clonality of leukemic cells is analyzed by sequencing of TCR gamma and 
delta chain (TCR-γ/δ) rearrangement. Standardized protocols have been developed by 
the BIOMED-2 consortium.20,21 Although T-LGL leukemia cells usually express 
TCR-α/β, the previously rearranged gamma chain is not deleted during the subsequent 
rearrangement process of the α/β genes and thus can be used in the DNA-based 
clonality assay. The TCR β-chain variable (V) region repertoire can be assessed using 
monoclonal flow cytometry antibodies, which recognize about 75% of the total 
spectrum of Vβ.22 Unlike PCR methods, this assay gives also a quantitative estimate 
of the number and size of T cell expansions.  
 
2.3. Laboratory diagnostics of CLPD-NK 
CLPK-NK cells are usually CD2+ CD3neg CD4neg CD8neg CD16+ CD56+, and 
often also CD57+; however, the expression of the common NK cell marker CD16 can 
vary (Table 1).2,7,15 TCR clonality testing is not applicable in CLPK-NK, and no 
definite method for clonality analysis exists, unless leukemic cells harbor cytogenetic 
abnormalities. NK-type LGLs express killer immunoglobulin-like receptors (KIR) on 
their surfaces: in CLPD-NK, possible monotypic or skewed expression pattern may 
be observed by using monoclonal antibodies to CD158a, CD158b, and CD158e, but 
testing is not widely used outside of research settings.23  
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2.4. Hematological aberrations 
The largest cohort describing the clinical characteristics of LGL leukemia patients 
included 229 French patients (209 T-LGL, 27 CLPD-NK, and 1 aggressive NK-
LGL).12 In this cohort, 51% of T-LGL and 54% of CLPD-NK patients had absolute 
lymphocyte counts >4x109/l, but the absolute LGL count was <1x109/l in 36% and 
47% of the study patients, respectively.12 The mean LGL count in the whole series 
was 1.7x109/l.12 Neutropenia (<1.5x109/l) was the most common cytopenia observed 
(61% and 48% in T-LGL and CLPD-NK, respectively), and a marked proportion of 
the patients (26% and 16%) presented with severe neutropenia (<0.5x109/l), whereas 
anemia (24% and 28%) and thrombocytopenia (19% and 8%) were rarer.12 Recurrent 
infections related to neutropenia were commonly seen in both T-LGL (23%) and 
CLPD-NK (18%).12 The results from the French cohort were concordant with other 
large previously published series.7,24 
The mechanism of neutropenia is probably multi-factorial and related to both 
impaired myeloid proliferation and increased peripheral destruction. The level of 
circulating FAS ligand (FASL) is elevated in LGL leukemia patients, and the serum 
of LGL leukemia patients triggers apoptosis of neutrophils, as normal neutrophil 
survival is regulated by the FAS-FASL system.25 Anti-neutrophil antibodies in LGL 
leukemia patients’ sera could also cause neutropenia in an immunocomplex-mediated 
mechanism.2 The infiltration of BM in LGL leukemia is often subtle—even non-
existent—in some patients, and cannot explain neutropenia in LGL leukemia patients 
when compared with acute leukemias in which the massive infiltration of leukemic 
blast cells causes profound cytopenias.26 However, the BM microenvironment seems 
to be dysregulated in LGL leukemia: severe fibrosis was connected to LGL BM 
infiltration and associated with the presence of cytopenias.27  
The most common hematological aberrations and even malignant conditions 
associated with LGL leukemia are different B cell dyscrasias ranging from polyclonal 
hypergammaglobulinemia to monoclonal gammapathy of unknown significance 
(MGUS), and lymphoma.28,29 In a cohort of 63 patients, coexisting B cell 
abnormalities were identified in 43% of the patients.29 These included both nonclonal 
conditions such as hypergammaglobulinemia/hypogammaglobulinemia (16%) and 
clonal disorders including MGUS (19%), chronic lymphocytic leukemia (CLL) (8%), 
and follicular lymphoma (2%). In another study, abnormal monotypic B cell 
populations (monoclonal B cell lymphocytosis, MBL) were detected by flow 
cytometry in 28% of 57 LGL leukemia patients.28 MBL can also be seen in healthy 
elderly individuals without apparent lymphocytosis, with a prevalence of 5%.30 When 
associated with elevated lymphocyte counts, MBL is a known risk factor for CLL.30 
The French cohort showed different gammapathies in 47% of patients, and the most 
common neoplasms were lymphomas (7%).12 The pathogenetic mechanism leading to 
concurrent LGL and B cell expansion is not known: LGL leukemia possibly has either 
developed in response to antigenic stimulation caused by abnormal B cell population 
or vice versa, or both populations have developed independently in response to the 
same or different antigens.28 The relationship of other neoplasms to LGL leukemia 
has not been confirmed to the same extent.12 
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2.5. Autoimmune manifestations 
The incidence of autoimmune diseases is higher in LGL leukemia patients than in 
the normal population and the patients can present with signs and symptoms of 
autoimmunity before LGL leukemia is diagnosed; 34% of LGL leukemia patients 
manifest with some type of autoimmune disorder.12,31 The most common concomitant 
disorder is rheumatoid arthritis (RA), which is more common in T-LGL leukemia 
than in CLPD-NK, and seen in 11-36% of patients, depending on the study cohort 
(Table 1).7,12,24 Felty’s syndrome is a rare complication of RA, characterized by the 
clinical triad of RA, splenomegaly, and neutropenia. Felty’s syndrome and LGL 
leukemia have similar clinical and laboratory manifestations, with the Human 
leukocyte antigen-DR4 (HLA-DR4) haplotype as a predisposing factor.32 Both have 
aberrations in the T cell population, such as a skewed T cell receptor rearrangement 
repertoire, and they probably share the same pathogenetic mechanism.33,34 
Autoimmune cytopenias can occur concomitantly with LGL leukemia: in the 
French, cohort the prevalences of pure red cell aplasia (PRCA) and autoimmune 
hemolytic anemia (AIHA) were 3% and 4%, respectively.12 However, PRCA is 
remarkably more common in Asian populations, with prevalence of 47% in LGL 
leukemia patients, whereas neutropenia, which is common in Caucasian patients, is 
almost nonexistent in Asian cohorts.35 The reason for this difference is not known. 
Other autoimmune disorders such as Sjögren’s syndrome, different vasculitis, 
endocrinopathies, and chronic inflammatory bowel disease are sometimes associated 
with LGL leukemia.12,36 
 
2.6. Differential diagnosis of LGL leukemia 
The diagnosis of LGL leukemia is based on many factors, and even clonality of 
expanded lymphocytes is not a definitive marker for the diagnosis. Several benign 
conditions can mimic LGL leukemia; the incidence of oligoclonal or small 
monoclonal asymptomatic T cell populations is increased with age, and in one 
previous study clonal T cells were seen in all (14/14) subjects older than 65 years.37,38 
Transient or even persistent oligo/monoclonal T lymphocytosis is sometimes seen 
during viral infections. For example, some HIV infected patients have circulating 
clonal CD8+ LGL expansions, which show cytotoxic properties against viral core 
protein.39 Human cytomegalovirus (CMV) stays in the body as a latent form, and 
immunocompetent individuals often have clearly detectable amounts of CMV 
antigen-specific T and NK cells, both during primary infection and at later 
timepoints.40 Clonal T cells and increased amounts of NK cells can also be seen in 
chronic myeloid leukemia (CML) patients during tyrosine-kinase inhibitor 
therapy.41,42 While repeated examination of clinical characteristics, laboratory values, 
and clonality can differentiate most of these conditions of T cell lineage, similar 
evaluation of NK-lineage processes is more complicated because of the lack of good 
clonality marker.3 
Different T and NK neoplasms also need to be taken into consideration while 
establishing the diagnosis of LGL leukemia. These include, for example, T cell 
prolymphocytic leukemia (T-PLL), hepatosplenic T cell lymphoma, extranodal NK/T 
cell lymphoma of the nasal type, and aggressive NK cell leukemia.10 T-PLL and 
hepatosplenic T cell lymphoma both have more aggressive clinical courses, marked 
hepatosplenomegaly, and cytogenetic abnormalities, and the immunophenotype of the 
leukemic cells differs from LGL leukemia (usually CD4+ or CD4+CD8+ in T-PLL 
and CD4negCD8neg in hepatosplenic T cell lymphoma).43,44 NK cell-originating 
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malignancies are aggressive neoplasms, which are thought to associate with Epstein-
Barr virus (EBV). They are rare in Western countries, in contrary to Asian and South 
American populations.45 In particular, NK cell leukemia has an extremely fatal 
course, with poor median survival of less than two months.46 A rare subtype of T-
LGL leukemia, separate from the indolent T-LGL form, is characterized by the 
expansion of CD56-expressing T-LGLs, B symptoms (fever, night sweat, and weight 
loss), lympadenopathy, and splenomegaly.19 It is resistant to immunosuppressive 
therapy.19 Unlike aggressive NK-LGL leukemia, no connection to EBV infection has 
been detected.19 
Post-transplant lymphoproliferative disorders (PTLD) are potentially fatal 
conditions that develop after either solid organ or hematopoietic stem cell 
transplantation, and their clinical presentation varies from polyclonal lymphoid 
hyperplasia to aggressive lymphoma.47 PTLD originates from B cells, and is in most 
cases associated with EBV.48 
Autoimmune lymphoproliferative syndrome (ALPS), which is caused by genetic 
defects in FAS-mediated apoptosis (usually loss-of-function mutations in the 
intracellular domain of FAS), presents typically as chronic lymphoproliferation, 
hepatosplenomegaly, autoimmune diseases, autoimmune cytopenias, and increased 
incidence of cancer. The mutations can be either germline or somatic, but the disease 
is usually diagnosed in childhood and the phenotype of the massive 
lymphoproliferation is CD4neg CD8neg.49,50 
 
Table 1. Clinical characteristics of T-LGL leukemia and CLPD-NK. 
Type Hematological 
findings 
Flow 
cytometry 
markers 
Clonality 
analysis 
Clinical features Auto-
immune 
conditions 
T-LGL PB LGL count 
>0.5x109/l. In 
appropriate 
clinical 
context PB 
LGL count 
can be 
<0.5x109/l. 
CD3+ 
CD8+ 
CD16+ 
CD57+ 
TCR-α/β+ 
PCR method 
(TCR-γ) or 
flow 
cytometry 
(Vbeta) 
Splenomegaly, 
cytopenias, recurrent 
infections, 
splenomegaly, LGL 
infiltrates in BM and 
liver, B cell dyscrasias  
Rheumatoid 
arthritis 
common 
CLPD-
NK 
CD3neg 
CD16+ 
CD56+ 
Flow 
cytometry 
KIR analysis 
(not common 
in the clinic) 
Rheumatoid 
arthritis rare 
Abbreviations: BM, bone marrow; KIR, killer cell immunoglobulin-like receptor; PB, peripheral 
blood; TCR, T cell receptor; Vbeta, T cell receptor beta chain variable region. 
 
 
3. Treatment of LGL leukemia 
The pharmacological therapy in LGL leukemia is connected to the related 
cytopenias and concomitant autoimmune disorders: the indications for treatment 
include severe neutropenia (neutrophil count repeatedly <0.5x109) or moderate 
neutropenia with infections, symptomatic anemia, and related autoimmune diseases 
(most often RA).51 Prospective large trials concerning the selection of treatment have 
not been published and no standardized therapy guidelines exist. Current treatment 
with immunosuppressive agents is based on data from retrospective series. A 
schematic suggestion for LGL leukemia treatment is presented in Figure 2. 
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3.1. Immunosuppressive treatment 
The most commonly administered first-line treatment is low-dose oral 
methotrexate (MTX), which has also been used to treat RA.52 The first report of MTX 
in LGL leukemia (including 10 patients) described overall response rate (ORR) of 
60%, and responses were durable during follow-up (range 1.3-9.6 years).53 In the 
French cohort, ORR was also 55%.12 However, relapse rates were marked: 12/18 
(67%) of the patients who were followed for more than one year did not maintain 
remission.12 If a response is achieved, continuous MTX is recommended.51 
The alkylating agent cyclophosphamide has been especially used as a second-line 
treatment: ORR in the French cohort was 66%, and 11/15 patients responded even 
after failure to first-line MTX.12 It was first used to treat LGL leukemia with 
concomitant PRCA, in which it was effective, with 75% (6/8) ORR.54 In the first-line 
setting, the results are also promising: ORR was 71% (32/45) and 47% achieved 
hematologic CR.55 ORR was similar in T-LGL leukemia (72%) versus CLPD-NK 
(68%) and in neutropenic patients (72%) versus anemic (67%) patients.55 The median 
treatment duration for responders was 8.5 months: long cyclophosphamide-
monotherapy regimens are not recommended because of the risk of secondary 
malignancies such as myelodysplastic syndrome (MDS) or acute myeloid leukemia 
(AML).56 The relapse rate was low (13%) and grade 1 and 2 toxicities were seen in 
18% of patients.55  
Cyclosporine A is also used to treat LGL leukemia, as an alternate therapy to 
MTX and cyclophosphamide.51 ORR in LGL leukemia with PRCA is comparable to 
cyclophosphamide, but relapse is common if treatment is discontinued.54 In another 
study, the ORR was much poorer: only 21% after three months of treatment.12 
 
3.2. Other therapies 
The effects of glucocorticoids such as prednisone are not remarkable in the 
treatment of LGL leukemia: in a group of 22 LGL leukemia patients, only two 
achieved PR or CR with first-line steroid therapy.12  
Neutropenia is associated with recurrent, even fatal, bacterial infections in LGL 
leukemia.12 Granulocyte colony-stimulating factor (G-CSF) has some efficacy in 
elevating neutrophil levels in case reports and small patient series.57,58 Prospective 
studies concerning the efficacy of G-CSF in neutropenic fever and sepsis of LGL 
leukemia patients have not been done. The effects of G-CSF have been studied in 
neutropenia related to Felty’s syndrome, where it improved neutrophil counts.59 The 
same authors performed a systematic review of literature, and G-CSF proved to be 
effective at elevating neutrophil counts, which was often associated with 
improvement of infectious complications.59 In the French cohort, 14 patients had a 
poor or transient response in neutrophil levels when G-CSF was used as a 
monotherapy.12 
Alemtuzumab is a recombinant humanized monoclonal antibody directed against 
the pan-lymphocyte antigen CD52. It has also been used in LGL leukemia with some 
success, and even some refractory patients have had durable responses in case 
reports.60,61 Studies of larger patient cohorts have not been published. 
LGL leukemia patients with splenomegaly have multilineage cytopenias with 
higher frequency compared to patients with normal spleen size, and splenectomy 
induces a hematological response so that patients achieve transfusion-independence.62 
First-line splenectomy was efficient in 4 of 10 patients studied in the French cohort.12  
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3.3. Evaluation of treatment response 
The treatment response should be evaluated four months after the onset of the 
therapy.51 In a hematologic complete response (CR), the blood counts are normalized: 
hemoglobin >120 g/L, neutrophil count >1.5x109/l, lymphocytes <4x109/l, neutrophils 
>1.5x109/l, and circulating LGLs are in the normal range.51 A complete molecular 
response (CMR) is characterized by the disappearance of the T cell clone using a PCR 
method.51 The term hematologic partial response (PR) is used when blood counts are 
improved, but do not fulfill the criteria for CR.51 The term treatment failure is used 
when none of the response criteria are met during first four months of therapy.51 
 
3.4. Prognosis of LGL leukemia 
The prognosis of LGL leukemia is relatively good: most patients display a non-
progressive chronic clinical course despite the presence of severe cytopenias, 
infections, and autoimmune disorders.63 The survival rates vary between different 
studies. In the publication originally describing LGL leukemia, 9 of 25 patients died, 
primarily due to infections, during follow-up of over two years, and in the French 
cohort 25/229 patients died, related mostly to neutropenic sepsis.7,12 Median survival 
was reported to be 161 months in one study.64 The majority of patients required 
treatment at some time during the follow-up of ten years.51  
 
 
 
Figure 2. Schematic representation of LGL leukemia treatment (modified from the 
review by Lamy and Loughran, Blood, 201151) 
 
Diagnosis of 
LGL leukemia
No symptoms No treatment, follow-up
Symptomatic
Anemia Neutropenia Autoimmune disorder
FIRST-LINE TREATMENTMTX or cyclophosphamide MTX ± Prednisone
Evaluation at 4 months
CR/PR
Continue
Failure
Switch to MTX/
cyclophosphamide (or CyA
in case of anemia)
SECOND/THIRD-LINE TREATMENT
Failure of second/third-line
treatment
Alemtutsumab/
investigational drugs
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4. Survival signaling in LGL leukemia 
4.1. T cell receptor rearrangement and antigen specificity 
The etiology of LGL leukemia is unknown. The phenotype of T-LGL, the 
effector-memory cytotoxic lymphocyte, suggests antigen stimulation behind leukemic 
expansion. The vast majority of T-LGL leukemia expansions express α/β-type TCR 
on their surface, and TCR-γ/δ LGL leukemia is rare.16 The β chain is composed of 
rearranged variable (V), diversity (D), and joining (J) segments and a constant region, 
whereas the α gene consists of only V and J segments.65 During T cell development, 
the TCR-α/β genes rearrange in a unique manner, and with junctional deletions and 
insertions, this recombination produces an incredible number of different 
combinations, thus creating the vast pool of T cells recognizing different antigens.65 
TCRα/β forms the TCR-CD3 receptor complex with different CD3 chains, in which 
TCRα/β is responsible for the antigen recognition and the CD3 chains transduce the 
signal inside cell, enhanced by coreceptors (CD4 or CD8). The TCRβ chain has three 
complementarity-determining regions (CDRs): CDR1 and CDR2 interact with 
antigen-presenting major histocompatibility (MHC) molecules stabilizing the antigen-
TCR ligation while the hypervariable CDR3 region is responsible for the actual 
antigen recognition.66,67 When a T cell encounters its specific antigen for the first 
time, contact between MHC/antigen complex of antigen-presenting cell and TCR of T 
cell causes changes in TCR and coreceptor conformation, resulting in binding of the 
cells to each other with high affinity. Simultaneously, different cytokines related to 
the immune response strengthen and guide the T cell activation and proliferation into 
effector T cells, which are capable of exerting different functions required for the 
clearance of the antigen, and do not need further co-stimulatory receptors in order to 
act if they encounter the antigen again. 
A few studies have concentrated on elucidating the possible antigen target behind 
leukemic T-LGL expansion by using the analysis of TCRβ CDR3 repertoire. 
However, a specific antigen can be recognized by a large number of different TCR 
types and the variation in peptide-presenting HLA genes between individuals also 
affects the recognition, but in the context of the same HLA type, TCRβ CDR3 
rearrangement seems to be typical for the antigen target.68-70 Some T-LGL leukemia 
patients are reported to have identical TCRβ immunodominant clonotypes; sharing of 
similar major clonotypes or smaller expansions is even more common. In contrast, the 
physiological TCR repertoire in healthy individuals is diverse and common CDR3 
rearrangements are not normally detected.71  
The immunodominant clones in T-LGL leukemia can sometimes change through 
a phenomenon called clonal drift.72 In a follow-up study with quantitative Vβ flow 
cytometry analysis of the TCR clonality, the patients represented four different 
patterns of TCR Vβ development during the course of the disease: of 71 analyzed T-
LGL leukemia patients, 54% and 10% had either persistent large LGL expansion or 
had a slowly rising proportion of the same immunodominant clone during follow-
up.72 The rest had another type of TCR Vβ pattern: 20% of the patients displayed a 
rise in the major clone from the initially polyclonal-appearing background, and in 
17% of the cases, the major clone disappeared while another clonal expansion 
simultaneously evolved.72 
Despite the data suggesting restricted use of TCR repertoire in LGL leukemia, no 
common antigens causing clonal persistent lymphocyte expansions have been 
recognized. Considering infectious agents and LGL leukemia, the connection between 
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lymphoid malignancies and certain pathogens is well established. For example, 
Epstein-Barr virus (EBV) is often associated with rare aggressive NK-LGL leukemia 
and Hodgkin lymphomas.73,74 Increased levels of human T lymphotrophic virus 
(HTLV) antibodies have been detected in T-LGL leukemia patients’ sera (44% vs 
0.12% in healthy controls), but only a minority of these patients (7.5%) were actually 
infected with HTLV-2 when analyzed with a HTLV-2-specific PCR method.75 This 
could be explained by serologic crossreactivity to a cellular or retroviral antigen 
showing some amino acid sequence homology with the HTLV antigen. Similar 
seroreactivity to HTLV is seen in CLPD-NK patients sera, but no trace of HTLV 
nucleic acids were detected by PCR.76 Rheumatoid arthritis, other autoimmune 
diseases, and autoimmune cytopenias are overrepresented in LGL leukemia patients, 
but no direct evidence of crossreactivity between pathogens and autoantigens exists. 
 
4.2. NK cell receptors in CLPD-NK 
NK cells are part of the innate immune system and are involved in immune 
surveillance against virus-infected and tumor cells. NK cells express various 
activating and inhibitory cell surface receptors, which control their ability to directly 
kill target cells and produce different cytokines. Normal NK cells express three types 
of receptors: killer cell lectin-like receptors (KLRC), killer cell immunoglobulin-like 
receptors (KIR), and natural cytotoxic receptors (NCR).77 KIRs are divided into 
activating and inactivating receptors: Activating KIRs detect infectious ligands such 
as virus particles and also self-ligands from, for example, transformed malignant 
cells, whereas inhibiting KIRs ensure tolerance to self, but also give the ability to 
recognize the “missing self” on transformed cells.78 NK cells express different co-
receptors such as CD56 and CD16. The CD56dimCD16+ NK cells display potent 
cytolytic function when activated, whereas the CD56brightCD16+/- NK cells, which are 
thought to be the precursors of CD56dim cells, are poorly cytolytic but secrete 
different cytokines.79 
In healthy individuals, the NK cell receptor repertoire differs between individuals 
due to genetic background, but is consistent within one individual.80,81 As a rule, 
every NK cell has at least one inhibiting NK cell receptor to ensure self-tolerance.80,81 
In a study of CLPD-NK, 11 of 18 patients expressed homogenously one KIR on the 
surface of NK cells, and further examination of in vitro cultured NK cell lines derived 
from 7 patients revealed the homogeneous expression of at least one activating KIR.82 
In another study, CLPD-NK cells also expressed activating KIR and the expression of 
inhibitory receptors, determined by RT-PCR, was lower in comparison to normal 
cells.83 Leukemic NK-LGLs possess potent cytolytic activity in cytotoxicity assays, 
which could be related to the increased activating–to-inhibitory KIR ratio, and 
resulting inappropriate cytotoxicity or cytokine secretion can impact CLPD-NK 
pathogenesis.83 
 
4.3. Impaired FAS/FASL-induced apoptosis 
The encountering of its specific antigen by a T cell results in rapid proliferation of 
clonal effector cells during the first few days after the antigen recognition. These cells 
could cause harm if the response continues uncontrolled; therefore, activated T cells 
undergo activation-induced cell death (AICD), which leaves only a small memory cell 
population and is important for the maintenance of self-antigen tolerance.84 When 
cytotoxic lymphocytes are activated, transcription of both FAS and FASL is 
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upregulated. Binding of FASL to FAS results in trimerization of FAS, which in turn 
enables binding of FAS-associated protein with death domain (FADD) to the 
intracellular part of the FAS trimer. The FAS trimer-FADD complex is called the 
death-inducing silencing complex (DISC).84 The proapoptotic protein procaspase-8 
binds to DISC and is cleaved to its active form caspase-8, which is capable of 
activating the downstream apoptotic pathway.84 
One of the major molecular defects in LGL leukemia is resistance to FAS-
mediated apoptosis, despite high levels of FAS and FASL (Table 2). 4,85 Impairing 
mutations in FAS are associated with lymphoproliferative disease and autoimmunity, 
but have not been found in LGL leukemia.85,86 After PHA and interleukin-2 (IL-2) 
stimulation, LGL cells from almost all patients gained sensitivity to FAS-mediated 
apoptosis, suggesting that the actual FAS/FASL machinery in leukemic LGL is 
intact.85 
  
4.4. Activation of STAT3 
Aberrant and constitutive STAT3 activation is common in different malignancies 
and is caused by overactive tyrosine kinases arising from genetic or epigenetic 
alterations. The effects of constitutively active STAT3 depend on the cell type and co-
activating proteins.  
STAT3 is constitutively activated in LGL leukemia and seems to be connected to 
impaired sensitivity to FAS-mediated apoptosis: in electrophoretic mobility shift 
assays (EMSAs), STAT3 was localized in the nuclei of all (n=19) T-LGL leukemia 
cells, mostly as the sis-inducible element (SIE)-binding STAT3:STAT3-homodimers. 
The STAT3 phosphorylation levels were also higher in LGL leukemia samples 
compared to healthy controls and inhibition of STAT3, either by a JAK-inhibitor or 
direct STAT3-antisense-nucleotide method, restored FAS-mediated apoptosis and 
was associated with decreased expression of anti-apoptotic Myeloid cell leukemia-1 
(MCL-1) protein (Table 2).4 
 
4.5. PI3K/RAC/PAK/MAP2K-, PI3K/AKT-, and PI3K/NFκB-pathways  
The Phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K)/Ras-related C3 
botulinum toxin substrate (RAC)/P21 protein (Cdc42/Rac)-activated kinase (PAK)/ 
Mitogen-activated protein kinase kinase (MAP2K)-, PI3K/V-akt murine thymoma 
viral oncogene homolog (AKT)-, and PI3K/Nuclear factor kappa B (NFκB)-pathways 
are antiapoptotic signaling cascades that play critical roles in the transmission of 
signals from cell surface and intracytoplasmic receptors to regulate gene expression.87 
Components of these pathways are mutated or aberrantly expressed in different 
malignancies, and activating mutations in upstream regulators can also induce these 
pathways.  
The cytotoxic activation of NK cells starts by the ligation and recognition of a 
target cell to the NK cell receptors. This triggers the activation cascade 
PI3K/RAC/PAK/MAP2K, which leads to the mobilization of lytic granules 
containing granzyme B and perforin toward the target cell.77,88 The inhibition of this 
pathway leads to apoptosis of leukemic LGLs (Table 2).89 The reason for constitutive 
phosphorylation and activation of the pathway is not known, but it could be related to 
the increased activating-to-inhibitory KIR ratio seen in leukemic NK-LGL.83,89 The 
pathway is also activated in T-LGL leukemia.90 
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PI3K is also an upstream regulator of AKT, and the PI3K-AKT pathway is 
activated in T-LGL, depending on Src family kinases (Table 2).90 Inhibition of the 
pathway leads to rapid FAS-mediated apoptosis of leukemic LGLs.90 In a network 
model of survival signaling in LGL leukemia, PI3K-inhibition led to NFκB-inhibition 
and apoptosis, independent of AKT.91 NFκB was also shown to inhibit apoptosis 
through MCL-1, independent of STAT3.91 The PI3K activation could be related to 
increased cytokine production: leukemic T-LGLs constitutively produce the 
proinflammatory cytokines Chemokine (C-C motif) ligand 5 (CCL5), Macrophage 
inflammatory protein-1 (MIP-1), and IL-18, which all have been shown to induce the 
PI3K.90,92 
 
4.6. IL-15 and PDGF signaling 
IL-15, along with IL-2, stimulates proliferation of T cells, induces development of 
cytotoxic T cells, and maintains NK cell population.93 The IL-15-receptor (IL-15R) 
and IL-2R contain the same β and γ subunits in addition to the specific IL-15Rα or IL-
2Rα subunits, and they both induce the same downstream proteins such as JAK1, 
JAK3, PI3K, and Spleen tyrosine kinase (SYK).93 However, IL-2 and IL-15 have 
distinct roles in T cell homeostasis: IL-2 is involved in AICD, elimination of 
autoreactive T cells, and promotion of the development of regulatory T cells, whereas 
IL-15 maintains the activated CD8+ memory cell population.94-96 IL-15 transgenic 
mice first develop CD3+ and CD3neg LGL expansions, which transform into fatal 
leukemia.97 Similarly, transduction of retroviral IL-15 vector to human CD8+ cells 
leads to clonal, cytokine-independent growth of CD8+ cells.98 
Platelet-derived growth factors (PDGFs) are able to activate a number of 
downstream signaling cascades such as PI3K-AKT and JAK-STAT, and dysregulated 
PDGF signaling is associated with multiple malignancies.99,100 The PDGF family 
consists of four gene products, which form five different isoforms and act via two 
receptor tyrosine kinases: PDGF receptors α and β.101 
In a network model of survival signaling in LGL leukemia, the known 
dysregulations and survival signaling network of normal cytotoxic lymphocytes were 
integrated into one model, and the prediction was that the initial T cell activation, 
constitutive presence of IL-15, and activated PDGF signaling can sustain leukemic 
LGLs and produce all known signaling dysfunctions in LGL leukemia (Table 2).91 IL-
15 has previously been connected to LGL leukemia pathogenesis: both CD3+ and 
CD3neg LGL were stimulated by IL-15, and IL-15 enhanced their cytotoxicity.102 In 
that study, IL-15 was probably secreted by monocytes, and it was bound to the 
membranes of the LGLs.102 PDGF levels were elevated in the sera of LGL leukemia 
patients compared to the healthy controls, and inhibition of PDGF induced apoptosis 
of leukemic LGL.91 
 
4.7. Altered sphingolipid-mediated signaling 
Gene expression data from normal and normal phytohaemagglutinin (PHA)- and 
IL2-stimulated PB mononuclear cells (MNCs) were compared with leukemic LGLs. 
Interestingly, normal stimulated PB MNCs show upregulation of both prosurvival and 
proapoptotic pathways, probably related to the strict control of the T cell population 
with AICD seen in normal lymphocytes after activation and proliferation.103 In 
contrast, in leukemic LGLs, genes and pathways related to leukocyte activation were 
upregulated simultaneously with antiapoptotic pathways, indicating the failure of 
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AICD.103 The most clearly upregulated genes in a comparison of healthy stimulated 
PB MNCs and leukemic LGLs were tumor necrosis factor alpha-induced protein 3 
(TNFAIP3)(NFκB inducible gene), antiapoptotic MCL-1, and different sphingolipid-
metabolism related genes (Table 2).103 The authors were especially interested in 
sphingosine-1-phosphate (S1P), which is generated when ceramidase converts 
ceramide to sphingosine, and sphingosine kinase subsequently converts it to S1P.104 A 
ceramide–sphingosine–S1P rheostat has a role in multiple malignancies: ceramide and 
sphingosine are proapoptotic, whereas S1P promotes cell survival.104 Antiapoptotic 
S1P promotes tumor growth and inflammation through both intracellular and receptor 
mediated mechanisms.104 Inhibition of acid ceramidase by N-oleoylethanolamine 
(NOE, mechanism of inhibition unknown) and administration of FTY720 (binds S1P-
receptors with high affinity and induces S1P downregulation) induced apoptosis of 
leukemic LGLs and had little effect on normal PB MNCs.103 
 
Table 2. Summary of dysregulated pathways in LGL leukemia. Superscript numbers 
refer to the cited references. 
Pathway Description 
FAS-FASL Leukemic LGLs are resistant to FAS-
mediated AICD, despite high levels of 
circulating FAS-FASL.4,85 
JAK-STAT STAT3 is constitutively active in LGL 
leukemia, and its inhibition leads to 
restored FAS-sensitivity, decreased 
expression of antiapoptotic MCL-1 and 
apoptosis of leukemic LGLs.4 
IL-15, PDGF In a network model of survival signaling 
in LGL leukemia IL-15 and PDGF are 
able to produce all known dysregulations 
in LGL leukemia.91 
PI3K/RAC/PAK/MAP2K The activation of PI3K in LGL leukemia 
can be related to the proinflammatory 
cytokines secreted by leukemic LGLs.92 
The pathway is related to the release of 
lytic granules toward the target cell of a 
cytotoxic lymphocyte. The inhibition of 
this pathway leads to apoptosis of 
leukemic LGLs.89 
PI3K/AKT Src activates PI3K-AKT pathway in LGL 
leukemia, and PI3K-AKT inhibition leads 
to FAS-mediated apoptosis of LGLs.90 
PI3K/NFκB PI3K inhibition leads to NFκB inhibition 
and apoptosis of leukemic LGLs and 
decreased MCL-1 expression.91 
Ceramide-sphingosine-S1P rheostat Sphingolipid imbalance is seen in LGL 
leukemia. Pro-apoptotic ceramide is 
decreased and anti-apoptotic S1P is 
increased.103 
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5. JAK-STAT signaling 
5.1. Overview of JAK-STAT signaling 
JAK-STAT signaling conveys signals of extracellular signaling peptides such as 
growth factors and cytokines from the cell surface into the cell and to the transcription 
of genes in the nucleus (Figure 3). The activation of the JAK-STAT pathway 
stimulates cell proliferation and migration, differentiation, and apoptosis. Historically 
speaking, the research into the JAK-STAT pathway started in 1957 with the discovery 
of interferon (IFN), which is one of the major stimulants of the pathway. By the end 
of the 1990s, the genomic and first crystal structures of STATs were described.105 
During the 2000s, the role of both inactivating and activating alterations in the 
pathway, seen in inherited diseases (germline mutations) and during malignant 
transformation (acquired somatic mutations), was studied and led to a deeper 
understanding of the pathway functions. 
The JAK-STAT pathway is activated when a ligand binds to an extracellular 
receptor and induces the multimerization of receptor subunits. The cytoplasmic 
domains of the receptors are associated with JAKs. JAKs represent a family of non-
receptor tyrosine kinases, and four members have been discovered: JAK1, JAK2, 
JAK3, and tyrosine kinase 2 (TYK2). Based on their crystal structure, they have four 
protein domains called kinase domain (called also Jak homology 1 [JH1] domain), 
pseudokinase domain (JH2), Src-like homology 2 domain (SH2) and FERM 
domain.106 Phosphorylation of tyrosine residues in the C-terminal kinase domain is 
essential for the binding of the substrate. The second domain, the pseudokinase 
domain, regulates JAK activity: for example, the JH2 domain of JAK2 
autophosphorylates two inhibitotory residues, and its function is crucial for the 
maintenance of low-level JAK2 activity in the absence of cytokine-induced 
activation.107 JAKs are activated when cell surface receptors multimerize and cause 
JAK-induced phosphorylation of both the cytokine receptors and their major 
substrates, STATs (Figure 3). STATs reside in the cytoplasm as latent monomers. 
Seven STAT family members have been recognized: STAT1, STAT2, STAT3, 
STAT4, STAT5A, STAT5B, and STAT6. They all have a SH2 domain and a 
conserved tyrosine residue near the C-terminus, which is phosphorylated by JAKs 
(Figure 4). Phosphorylated STAT monomers dimerize through reciprocal 
phosphotyrosine-SH2 interactions and enter the nucleus via various mechanisms 
depending on the STAT protein. In the nucleus, the STAT dimers bind to specific 
DNA elements with other transcription factors and change the transcription of their 
target genes (Figure 3).  
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Figure 3. Canonical representation of JAK-STAT signaling. 
 
5.2. Structure of STAT3, STAT5A and STAT5B 
The STAT3, STAT5A, and STAT5B genes are located on the long arm of 
chromosome 17 in adjacent regions (17q11.2). The protein structure of STAT3 and 
STAT5A/B consists of coiled-coil, DNA-binding, linker, SH2, and transcriptional 
activation (TAD) domains (Figure 4). STAT3 exists in two major isoforms: full-
length STAT3α is 770 amino acids long, while the shorter form STAT3β, arising 
from an alternative mRNA-splice site at exon 23, gives rise to a protein in which the 
last 55 C-terminal amino acid residues are replaced by 7 other residues. Thus, 
STAT3β lacks the TAD domain and seems to have specific functions of its own, as it 
can prevent the embryonic lethality of STAT3α-null mice and activate a set of STAT3 
target genes.108 The full-length STAT3α can exist in two isoforms: isoform 1 is one 
amino acid longer than isoform 2. STAT5A and STAT5B are separate genes. The 
coded proteins are 794 and 787 amino acids long, respectively, and are over 90% 
identical at the cDNA and protein level.109 The data for proteolytically cleaved 
isoforms of STAT5A or STAT5B are controversial and their existence has not been 
proved with certainty.110,111  
The dimer structure of STAT proteins is essential when they bind to the specific 
promoter sequences of the target genes. The crystal structure of a STAT3β 
homodimer bound to a short DNA fragment has been published (Figure 5, RCSB 
Protein Data Bank code 1BG1).112 According to the publication, residues K591, 
R609, S611, and S613 form polar interactions with phospho-Y705 of the other 
STAT3 monomer and are conserved among STAT family proteins.112 Phospho-Y705 
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and adjacent residues (702-709) are bound in a trans configuration to the opposite 
monomer, and the interaction is reciprocal (i.e., phosphotyrosine peptides of both 
monomers bind the monomers together).112 The side chains of residues T708, F710, 
and C712 interact with the other monomer, and differences in the sequences of these 
side chains between different STATs may explain the differences in 
homo/heterodimerization tendency of the members of the STAT protein family.112 
Residues 643-644 and 647-648 also take part in the dimer interface, independent of 
the phosphorylation status, which may explain the loose dimer association occurring 
without phosphorylation, although the N-terminal domain also plays a role in 
unphosphorylated dimerization.112 Another loop, which comes in close proximity to 
another STAT3 monomer, is situated nearer the C-terminal end, around amino acids 
656-677, and cysteine substitutes that form sulfhydryl bonds between monomers at 
A662 and N664 create a constitutively active STAT3 molecule.113 
The crystal structure of phosphorylated and DNA-bound STAT5A or STAT5B 
has not been reported yet. The structure of an unphosphorylated STAT5A dimer has 
been published (RCSB Protein Data Bank code 1Y1U).114 
 
 
 
Figure 4. Linear representation of common STAT protein structure. Tyrosine and 
serine residues that are phosphorylated during activation of STAT3 or STAT5A/B are 
marked in the structure. 
 
5.3. Activation and inactivation of STAT3 
STAT3 was originally described as an IL-6 dependent transcription factor 
promoting acute-phase gene expression in IL-6 treated hepatocytes, but it can mediate 
signals from the entire IL-6 and IL-10 families with a notable variety, as well as G-
CSF, leptin, IL-21, IL-27, protein tyrosine kinases such as Src and ALK, and receptor 
tyrosine kinases (epidermal growth factor [EGF], PDGF).115,116 The IL-6 receptor 
complex consists of two molecules: IL-6 receptor (IL6R) in which IL-6 is bound and 
gp130 (called also IL6 signal transducer, IL6ST), which has a long cytoplasmic 
tail.117 When IL-6 binds to IL-6R, it induces homodimerization of IL6ST: IL6ST does 
not have tyrosine kinase activity, but its cytoplasmic tail recruits JAKs, which can 
phosphorylate both IL6ST and STAT3.118,119 The JAKs associated with STAT3 
signaling are JAK1 and JAK2.120 Activated STAT3 forms dimers through reciprocal 
phospho-tyrosine-SH2 domain binding (Figure 5).121 Notably, unphosphorylated 
STAT3 can also exist in a homodimer form through N-terminal interaction, but the 
conformation of the dimer differs from the phosphorylated STAT3 dimer.122 STAT3 
can also be phosphorylated at S727: serine phosphorylation does not seem to 
influence the DNA binding of the STAT3 dimer, but it could affect the recruitment of 
other co-transcription factors.123 
Access to the nucleus is limited by different nuclear pore complex proteins, which 
are located in the nuclear membrane. Small molecules can diffuse through, but the 
access of larger proteins such as STAT3 is restricted to those that possess a protein 
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sequence specific for nuclear import and export. Unphosphorylated STAT3 can also 
be transported to the nucleus. The transport mechanism of both the unphosphorylated 
and phosphorylated forms is related to the function of importins, the most important 
probably being the importin-β1-importin-α3 heterodimer on the nuclear membrane.124 
In the nucleus, STAT3 dimers bind to DNA-response elements of target genes, named 
IFN-γ-activated sequence (GAS) or SIE, and activate specific gene expression 
programs, which are often anti-apoptotic, pro-proliferative, and oncogenic.125,126 
Phosphorylated and activated STAT3 also activates transcription of itself, and 
increased amounts of unphosphorylated STAT3 protein can subsequently be 
chaperoned into the nucleus by NF-kB, where it binds to κB elements of gene 
promoters and can alter the transcription of a subset of genes such as CCL5 (known 
also as RANTES) and IL-6.127 
STAT3 activation is reversed by different protein tyrosine phosphatases (PTPs), 
suppressors of cytokine signaling (SOCS), and protein activators of activated STATs 
(PIAS) (Figure 3).128 There are eight members of SOCS protein family, and their 
expression is induced by different cytokines. As negative feedback regulators, they 
inhibit JAK-STAT signaling by directly binding to JAKs and cytokine receptors: 
SOCS3 seems to be the most important inhibitor of STAT3 function.129 PIAS family 
proteins are located in the nucleus, and they inhibit and modify STAT3 signaling by 
blocking the DNA-binding of STAT3 and also by recruiting other transcription 
factors.130 PTPs remove phosphate from phosphorylated tyrosine residue of 
STAT3.131 
 
Figure 5. Three-dimensional model of dimerized STAT3, which has bound to the 
target DNA. The structure is predicted by Becker et al. Nature 1998112, and the RCSB 
Protein Data Bank code is 1BG1. Figure created with Swiss-PdbViewer (Swiss 
Institute of Bioinformatics). 
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5.4. Functions of STAT3 in different tissues 
STAT3 is essential for development, and total Stat3 ablation leads to early 
embryonic lethality in mice.132 Thus, the most widely used method to study the effects 
of STAT3 depletion in different tissues is through targeted Cre-loxP recombination 
with tissue specific promoters in a murine model.133 Targeted disruption of Stat3 
function in mouse T-cells results in impaired IL-6-mediated survival and reduced 
proliferative response when stimulated with IL-2.133 If Stat3 is absent in CD8+ 
lymphocytes, the levels of B cell leukemia/lymphoma 6 (Bcl6) and Socs3 are reduced 
and CMV-specific CD8+ T cells fail to transform into central memory T cells.134 
CD4+ T cell-specific Stat3 deletion results in impaired IL17-producing effector T 
helper cell (Th17) response, whereas retroviral expression of constitutively active 
Stat3 promotes Th17 development.135 Deletion of Stat3 from neutrophils and 
macrophages promotes abolishment of the suppressive effects of IL-10 on 
inflammatory cytokines from neutrophils and promotes the production of 
inflammatory cytokines from macrophages in response to endotoxins: consequently, 
the Th1-type response is enhanced and elderly mice develop chronic enterocolitis.133 
B cell-specific Stat3 deletion leads to reduced numbers of peripheral B cells and 
impaired plasma cell differentiation, resulting in a defective IgG response.136,137 
Targeted Stat3-deficiency in skin leads to a severely impaired hair cycle and wound 
healing.133 In liver, Stat3 is essential for the induction of inflammatory genes.138  
Heterozygous germline mutations in humans in DNA-binding and the SH2 
domain of STAT3 are seen hyper-IgE syndrome patients.139,140 The syndrome is 
characterized by recurrent staphylococcal infections, eczema, cyst-forming 
pneumonias, and high serum-IgE levels. The current hypothesis is that mutated 
STAT3 in hyper-IgE syndrome works as a dominant-negative protein: PB MNCs 
carrying these mutations respond poorly to IL-6-stimulation, and co-expression of the 
mutated protein with wild-type STAT3 leads to impaired DNA-binding and 
transcriptional ability of STAT3.139,140 The number of central memory CD4+ and 
CD8+ cells is reduced in hyper-IgE syndrome patients, related to the lower expression 
of BCL6 and SOCS3, and the development of a central memory T cell pool for 
varicella zoster and EBV is impaired, leading to poor control of latent infections.141 
IL6-STAT3 activation has been observed in many autoimmune and chronic 
inflammatory diseases. T cell-expressed STAT3 is required for the Th17 immune 
response, and aberrant function of Th17 response is linked with STAT3 
overexpression in RA, psoriasis, multiple sclerosis, and Crohn’s disease.142-145 
Inflammatory cytokines induce an IL-6-STAT3 activation loop in RA, and STAT3 
inhibition in a mouse model effectively reduced inflammation and destruction of 
synovial tissues.146 
 
5.5. STAT3 in cancer 
Tyrosine kinases such as JAKs are often overactive in cancer due to genetic or 
epigenetic alterations. Consequently, STAT3 activation is seen in many malignancies 
as a secondary event, one of the mechanisms being autocrine production of IL-6 or 
paracrine secretion of IL-6 by stromal or infiltrating inflammatory cells.147 The effects 
of constitutively active STAT3 depend on the cell type and co-activating proteins. 
STAT3 has many effects that promote tumor growth: it downregulates transcription of 
the common tumor suppressor tumor protein p53 (TP53), activates transcription of 
downstream anti-apoptotic proteins including BCL-XL and MCL-1, and prevents cell 
cycle arrest through v-myc avian myelocytomatosis viral oncogene homolog 
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(MYC).148 Aberrant STAT3 activation is often observed in head and neck cancer, 
multiple myeloma, breast cancer, and many hematological malignancies.149 STAT3 
activation in AML shortens the time of disease-free survival, although it did not affect 
OS.150 Interestingly, the oncogenic effects of STAT3 can be nongenomic and 
phosphorylation-independent: STAT3 is also located in the mitochondria, where it 
regulates cell metabolism and supports RAS-dependent malignant transformation.151 
STAT3 has also oncogenic potential on its own: a spontaneously dimerizing and 
constitutively active STAT3-molecule, STAT3-C, was created by cysteine substitutes 
of A662 and N664 in the SH2 domain.113  Mutated STAT3 is able to transform 
fibroblasts, and the transformed cells form tumors in nude mice.113  
 
5.6. Activation and inactivation of STAT5A and STAT5B 
Besides sharing the same chromosomal locus, STAT5A and STAT5B genes are 
also close functional relatives and share pleiotropic roles in mammary gland 
development, cytokine signaling, and immunoregulation in different tissues. STAT3 
and STAT5A/B also exhibit the highest degree of homology to invertebrate STAT 
genes.152 Of the two STAT5 proteins, STAT5A was first identified by its ability to 
mediate prolactin-induced upregulation of the expression of milk proteins. STAT5B, 
which was related to STAT5A with 96% sequence homology, was subsequently 
isolated. In this thesis, the term STAT5 refers to both STAT5A and STAT5B. 
STAT5 proteins transduce signals mediated through common γ-chain cytokine 
receptor families (IL-2, IL-7, IL-9, IL-15, and possibly IL-21), and also through IL-3 
(IL-3, IL-5, and GM-CSF) and single-chain (e.g. growth hormone, prolactin, thyroid 
peroxidase, and erythropoietin) cytokine receptor families.116 STAT5A and STAT5B 
are also activated through receptor tyrosine kinases such as EGF and PDGF.116 JAK3 
is exclusively associated with common γ-chain receptors, whereas also other cytokine 
receptors and receptor tyrosine kinases can activate JAK1.116 The effects of the single 
chain receptors are mediated by JAK2.116 
Phosphorylated STAT5 dimerizes and translocates to the nucleus, probably 
through the Chromosome region maintenance (CRM1) nuclear transporter protein.153 
Similar to STAT3, STAT5 can also shuttle to the nucleus in monomeric form.153 
STAT5 binds to GAS motifs of the target genes, and in particular, STAT5A can also 
bind to DNA as a tetramer, probably enhancing the transcription in comparison with 
the STAT5A-dimer.154 STAT5 regulates genes associated with apoptosis and cell 
proliferation: a recent study that utilized chromatin immunoprecipitation-sequencing 
(ChIP-Seq) showed high association between target genes of STAT5B, such as 
Dedicator of cytokinesis 8 (DOCK8), Forkhead box P3 (FOXP3), and IL2RA, and 
regulatory T cells (Tregs) and peripheral CD8+ cells and their activation, whereas 
STAT5A was involved in neural development and function.155 Surprisingly, another 
ChIP-seq experiment showed that the number of shared binding sites of STAT3 and 
STAT5 in T cells is greater than the number of shared binding sites of STAT5 in T 
cells and other cells.156 STAT5 regulates the CD8+ memory cell population by 
transmitting IL-2 and IL-15 signals.157 The inactivation of STAT5 signaling is similar 
to that of the STAT3 pathway, involving the PTP, SOCS, and PIAS protein families.  
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5.7. Functions of STAT5 in different tissues 
STAT5B is required for the development and normal function of lymphocytes. 
Germ-line deletion of either Stat5a or Stat5b gene in a mouse model does not lead to 
absolute embryonic lethality in the way that Stat3 deletion does. The first studies done 
with double Stat5a/b deficiency used a gene targeting strategy leading to an N-
terminally truncated and partially functional Stat5 proteins, and the results suggested 
that the effects of double deficiency were not that critical.158 However, recent studies 
have shown that total Stat5a/b deletion in mice leads to high perinatal lethality, severe 
combined immunodeficiency, and a lack of lymphoid cells, further emphasizing the 
pleiotropic role of Stat5 proteins in immune system function.159 
Stat5a-/- mice display impaired mammary gland development, whereas Stat5b-/- 
mice display impaired pituitary growth hormone production and consequently 
diminished body growth.160,161 Considering the function of the immune system, BM-
derived macrophages of Stat5a-/- mice exhibit defective GM-CSF–induced 
proliferation and gene expression in addition to other immunological defects, 
including a reduced number of T and NK cells in vivo.162,163 The T-cell defect is 
associated with diminished IL-2–mediated signaling.162,163 Stat5b-/- mice present with 
a diminished absolute number of NK cells and a maturation block in BM; the NK cell 
numbers are lower than in Stat5a-/- mice and NK-cell proliferation and cytolytic 
activity to IL-2 and IL-15 stimulation is poor.164 Stat3 and Stat5 are important 
modulators of Th17 differentiation, and they bind to multiple common sites of the 
Il17 locus: in murine models, Stat3 enhances Th17 response, whereas Stat5b 
conversely represses the transcription of Il17.135,165 
Impaired function of STAT5B caused by germline mutations has been described 
in humans in a few case reports: the patients are lymphopenic and have low numbers 
of CD4+CD25high Tregs, NK cells, and γδ-T cells.166-168 Clinically the patients present 
with growth retardation, interstitial pneumonia, severe eczema, and autoimmune 
disorders that are thought to be related to the dysfunctional T-regs.168   
 
5.8. STAT5 in cancer 
Constitutive STAT5 activation is an essential step in many malignancies such as 
CML and other myeloproliferative disorders (MPDs).169,170 In CML, oncogenic BCR-
ABL1 tyrosine kinase activates STAT5, and anti-apoptotic effects are conferred 
through transcription of antiapoptotic protein BCL-XL.130,171 ABL oncogenes do not 
induce malignant transformation in STAT5A/Bnull/null cells.172 Accordingly, STAT5 
inhibition induces apoptosis of CML cells.173 In other MPDs, STAT5 activation 
occurs through an activating JAK2 mutation, most commonly V617F, which has been 
observed in over 90% of patients with polycytemia vera and in 30-50% of cases with 
essential thrombocytosis or primary myelofibrosis.170 The V617F mutation is located 
in the JH2 domain of JAK2, and it abrogates the inhibitory function of the JH2 
domain.107 Downstream STAT5 activation is an essential step in the oncogenic 
transformation through V617F-mutated JAK2.174 Somatic JAK-mutations have been 
found in both adult and pediatric acute lymphoblastic leukemia (ALL) cases: the 
JAK1/2/3-mutations were seen in 20% of pediatric high-risk BCR-ABL1-negative 
cases and they caused constitutive STAT5 activation and cytokine-independent 
growth of Ba/F3-EpoR cell line.175,176 
Two constitutively active STAT5 mutants (STAT5-C) have been described. The 
first of these has two amino acid substitutions, H299R in DNA-binding domain and 
S711F in TAD.177 Cells transfected with STAT5-CH299R+S711F show increased STAT5 
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phosphorylation and transcriptional activity, and it sustains growth of IL-3-dependent 
cells in the absence of IL-3.177 The other published STAT5-C was created by one 
missense mutation N642H in SH2 domain, and it has similar properties as STAT5-
CH299R+S711F both biochemically and biologically.178 Notably, phosphorylation and 
dimerization are essential for the aberrant function of the STAT5-CN642H, and 
disruption of Y694 abolishes the acquired properties of STAT5-CN642H.178  
 
6. Cancer genetics and next-generation sequencing 
6.1. Oncogenes and tumor-suppressors 
Cancer results from the accumulation of genetic changes causing transformation 
of a normal cell.179 These alterations can occur in different types of genes, which can 
be divided into three groups based on their function: oncogenes, tumor-suppressor 
genes, and stability genes. Several genetic changes are usually required for malignant 
transformation because mammalian cells have several mechanisms that protect cells 
from the effects of harmful mutations. The mutations of oncogenes typically create a 
constitutively active form of the coded protein through chromosomal translocations, 
gene amplifications, or even by a single amino acid change in a crucial spot in the 
protein, and a heterozygous mutation is often sufficient to alter the function.179 On the 
other hand, usually both copies of the tumor-suppressor genes are damaged and 
inactivated by missense mutations in essential amino acids, deletions/insertions and 
larger chromosomal aberrations, or epigenetic changes.179,180 The function of stability 
genes is related to chromosome and DNA maintenance and error repair, and 
mutations in these genes increase the mutation rate of a cell due to genomic instability 
or increased vulnerability to the effects of mutagens.179 Lastly, genetic variants can be 
transmitted through the germline, in which case they are present in all the cells of an 
individual and contribute to inherited cancer susceptibility.181 
The term epigenetics refers to chromatin-based events, which regulate processes 
related to DNA template. These include for example DNA methylation, histone 
modification, and non-coding RNA molecules. Epigenetic pathways also play a 
significant role in oncogenesis alongside with genetic changes.182 
 
6.2. Next-generation sequencing technology 
Automated capillary (known as Sanger or chain-termination method) sequencing 
had been the gold standard of sequencing for over two decades and its 
accomplishments include the sequencing of the first human genome.183 Newer rapidly 
developing high-throughput sequencing methods are referred to as next-generation 
sequencing (NGS) or second-generation sequencing and their major benefit is the 
ability to produce a vast amount of data rapidly and inexpensively. The most popular 
methods are whole genome sequencing, whole exome sequencing (WES), RNA 
(transcriptome) sequencing, targeted sequencing, and ChIP-seq.184 In this review, the 
Illumina NGS platform will be used as an example.  
NGS technology consists of several steps which can be grouped as template 
preparation, sequencing and imaging, genome alignment and assembly, and data 
analysis.184  
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The template preparation method depends on the NGS application used. For 
example, in WES, the goal is to sequence the coding areas, consisting of 1% of the 
total genome. One method is to fractionate the DNA, ligate adaptors to the ends of the 
fragments, and subsequently capture fragments containing the exons using a kit 
consisting of custom oligonucleotides with magnetic beads.185,186 In targeted 
sequencing, primers with adapter tails are used to produce enriched amplicons of the 
targeted area, with adapter sequences at both ends of every amplicon. Illumina 
technology uses solid-phase amplification of the DNA fragments: fragments are 
attached to a glass slide by the adapter sequences.187 Adapter-specific forward and 
reverse primers are attached to the slide to produce 100–200 million spatially separate 
template clusters with bridging amplification strategy.184,187  
Clusters consisting of identical templates are essential to the sequencing, because 
most imaging systems cannot detect single fluorescent signals.184 In the sequencing 
and imaging step, the Illumina platform uses cyclic reversible termination, in which a 
fluorescent nucleotide with a terminating group is added to the primer-originating 
template, and imaging by lasers is performed to identify the nucleotide by 
fluorescence. The subsequent cleavage step removes the terminating group, enabling 
the start of the next incorporation cycle.184  
The nucleotide sequence of a template is called a read (the length being 
approximately 25-250 bp in Illumina NGS platforms). The reads are stored as a text-
based FASTQ file format, which contains both the sequence and quality scores (Phred 
score, in which score 20 corresponds to a 1% error rate) for every nucleotide.188 After 
the sequencing step, every raw read is aligned with a known reference sequence.189 
Different tools are used in this process, one of which is called the Burrows-Wheeler 
aligner (BWA), a software package for mapping short sequences against a large 
reference genome, such as the human genome.190 Sequencing data can be also 
visualized using different programs such as Integrative Genomics Viewer (IGV) but 
due to the vast amount of data, the next step (i.e., calling of variants from sequenced 
reads) is done with specific identification algorithms such as Varscan, which is 
developed for nomination of putative mutations, small insertions/deletions (“indels”), 
and copy number alterations.191-193 In the case of cancer exome/genome analysis, 
comparison of the patient’s tumor sample variants with the same patient’s germline 
data is essential for the identification of somatic variants and it can be accomplished 
with Varscan2 or similar software.191,194 Putative somatic mutations are annotated for 
functional consequences at gene and protein sequence levels, their conservation level 
in the evolution is estimated, and common variants seen in public databases such as 
1000 Genomes Project and dbSNP are identified and then excluded from further 
analysis.195  
 
6.3. Bias and error in NGS 
Every NGS platform has its own error profile. The quantity and quality of the 
source DNA affects the error rate and has to be taken into account: for example, 
compared to fresh samples, tissue samples stored as formalin-fixed and paraffin-
embedded (FFPE) blocks present a challenge for successful recovery of nucleic acids, 
which can be overcome with correct DNA isolation techniques.196 Template 
amplification can introduce mutations to DNA templates, which are then considered 
as true variants of the source DNA or can affect the correct alignment of the read.197 
Parallel analysis of a reference DNA sample with a known sequence gives an estimate 
of the error profile of the actual sample sequenced and analyzed.  
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The amount of sequencing data can be described with the term coverage or depth, 
which means the average number of times a base pair is sequenced in the experiment. 
The coverage seems to associate with certain genomic locations (with high GC 
content) in a reproducible way, and this can cause bias, especially in experiments in 
which coverage levels of different regions are compared (RNA sequencing, ChIP-
seq).198 The detection of single nucleotide variants (SNVs) and structural variants in a 
low-coverage area is more difficult, and the minimum median coverage recommended 
for NGS experiments is x20-30 to ensure proper detection of variants.199  
 The data for the newest Illumina instruments have not been published, but earlier 
Illumina sequencers such as GA and HiSeq2000 seem to produce mostly substitution 
errors, especially in GC-rich areas, while false indels are rarer.200 The error rate 
usually increases towards the end of the sequence (B-tail) and the quality of the data 
can be increased by trimming away the low-quality tails.198,200 This is explained by 
the fact that the cyclic reversible termination process can become desynchronized if 
the sequencing reaction in a cluster proceeds in dyssynchrony between different 
copies of a template, and this error type is prone to pile up towards the end of the 
template when dyssynchrony increases. 
 
 
  
 33 
AIMS OF THE STUDY 
 
The overall aim of this PhD project was to uncover the pathogenesis of LGL leukemia 
and find new molecular markers, which can be used in the diagnostics and targeted 
therapy. 
  
The project included four parts: 
 
1) The analysis of somatic genomic changes of LGL leukemia expansion in T-LGL 
leukemia patients 
 
2) Further characterization of STAT3 mutations and their clinical impact in T-LGL 
leukemia and CLPD-NK 
 
3) The pathogenesis of LGL leukemia in STAT3 mutation-negative patients 
 
4) The clonal hierarchy of expanded lymphocytes in LGL leukemia and the impact 
of STAT3 mutations on treatment responses 
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PATIENTS AND METHODS 
7. Patients and ethical permissions 
T-LGL leukemia and CLPD-NK patients included in studies I-IV were diagnosed 
based on WHO 2008 guidelines; the diagnostic criteria are explained in detail in the 
review of the literature of this thesis.9 The samples were collected at Helsinki 
University Central Hospital, Oulu University Hospital, Penn State Hershey Cancer 
Center (US), and Cleveland Clinic (US). The studies were conducted according to the 
Declaration of Helsinki and were approved by the Ethics Committees of Helsinki 
University Central Hospital, Penn State Hershey Cancer Center (US), and Cleveland 
Clinic (US). Written informed consents were obtained from patients and healthy 
controls in all studies. 
Study I aimed to analyze the molecular background of LGL leukemia by WES of 
leukemic LGLs and paired CD4+ cells. The STAT3 mutation of the index T-LGL 
leukemia patient was subsequently screened in a cohort, which consisted of 76 
additional T-LGL patients with a large immunodominant clone. In addition, 8 healthy 
controls, 10 AML patients, 8 ALL patients, 4 CML patients with reactive LGL 
expansion during dasatinib therapy, 2 CMV-infected patients, and one graft-versus-
host patient were analyzed as controls. DNA used in the STAT3 mutation analysis was 
extracted either from whole blood or PB MNCs. Clinical and functional consequences 
of STAT3 mutations were analyzed using patient samples and Hela-cell line. 
Study II included a larger LGL leukemia cohort: 120 T-LGL leukemia (the 
patients already analyzed in study I were excluded from this study) and 50 CLPD-NK 
patients. Samples from 31 patients with idiopathic neutropenia not fulfilling all 
diagnostic criteria for LGL leukemia were analyzed as well. The STAT3 mutation 
status was screened from the study cohort using capillary sequencing, and the source 
DNA was extracted from whole blood or PB MNCs. Due to the larger numbers of 
patients, clinical correlations were analyzed in greater detail in addition to the 
functional effects of the mutations. 
In study III, the molecular background of LGL leukemia in STAT3 mutation-
negative patients was analyzed by WES, followed by screening of novel STAT5B 
mutations from 173 T-LGL leukemia and 38 CLPD-NK patients. Additional control 
samples included 12 patients with reactive LGL lymphocytosis and 2 T-ALL cell 
lines (Jurkat and MOLT-4). HEK-cells were used in the functional analysis of 
STAT5B mutations. 
Study IV used deep targeted STAT3 sequencing and deep T cell receptor beta 
chain (TCRB) sequencing to analyze the clonal hierarchy in both T-LGL leukemia 
and CLPD-NK.  The original screening of STAT3 mutations was conducted on whole 
blood and PB MNC DNA. In addition, sorted lymphocyte fractions were analyzed 
from 13 STAT3 mutation-positive patients. The study cohort included both T-LGL 
leukemia (n=174) and CLPD-NK (n=39) patients. As a control, DNA was extracted 
from 8 CML patients with clonal LGL lymphocytosis during dasatinib treatment and 
from BM aspirates of 10 healthy controls. 
Some of the patients included in studies III and IV were the same ones analyzed in 
studies I and II.  
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8. Mononuclear cell separation 
Mononuclear cells were separated from peripheral blood using Ficoll-Paque 
gradient separation (GE Healthcare) according to the manufacturer’s instructions. The 
resulting PB MNCs were either used fresh, stored as pellets (at -70C), or 
cryopreserved in fetal bovine serum containing 10% DMSO. 
 
9. Flow cytometry analysis and selection/sorting of lymphocytes 
9.1. Magnetic bead separation 
In studies I and III, PB MNCs were labelled with magnetic CD4 or CD8 
MicroBeads (Miltenyi Biotech) and separated with an AutoMACS Cell Sorter 
(Miltenyi Biotech). In study III, NK cells were isolated with negative selection, which 
depletes T cells, B cells, monocytes, platelets, dendritic cells, granulocytes, and 
erythrocytes (Dynabeads Untouched human NK cells kit, Invitrogen). The purities of 
the sorted fractions were analyzed using flow cytometry (FACSAria, Beckman-
Coulter Immunotech). 
 
9.2. Fluorescence-activated cell analysis and sorting 
The TCR Vβ families were analyzed in studies I-IV using whole blood, fresh PB 
MNCs, or PB MNCs stored in liquid nitrogen. Samples were stained with a 
combination of monoclonal antibodies (mAb) against CD3, CD4, CD8 (BD 
Biosciences), and a panel of TCR Vβ mAbs corresponding to the 24 different families 
of TCR Vβ CDR3 region (Beckman-Coulter Immunotech)(Table 3). The kit 
recognizes about 70% of the normal human TCR Vβ repertoire: it consists of 8 tubes, 
each containing three different mAbs (PE-conjugate, FITC-conjugate, PE/FITC 
conjugate). Samples were analyzed with FACSAria/FACSAria II flow cytometers and 
FACSDiva software (Beckman-Coulter Immunotech) in studies I, III, and I. Study II 
utilized an FC500 flow cytometer with CXP Version 2.2 software (Beckman Coulter) 
and FCS Express Version 3.0 analysis software (De Novo Software). 
The KIR phenotype was analyzed in CLPD-NK cases in study II with mAbs 
targeting KIR2DL1, KIR2DS1/2/4, KIR2DL2/3/4, KIR3DL1, and NKG2A/D, using a 
2- or 4-color system (antibodies from BD Biosciences, Beckman-Coulter 
Immunotech, BioLegend). 
The analysis and sorting of lymphocyte subpopulations by flow cytometry 
(FACSAria/FACSAria II) was done in studies I-IV with different mAb panels 
targeting lymphocyte surface antigens (antibodies from BD Biosciences and 
Beckman-Coulter Immunotech)(Table 3). In addition, T-LGL clones were sorted in 
study IV using appropriate mAbs from TCR Vβ panel of Table 3 (Beckman-Coulter 
Immunotech). The purities of the sorted fractions were checked with flow cytometry.  
 
Table 3. Different flow cytometry antibody panels used in studies I-IV. 
 
TCR Vbeta analysis Lymphocyte subpopulations 1 Lymphocyte subpopulations 2 Lymphocyte subpopulations 3 
CD3 APC CD45 APC-Cy7 CD45 PerCP CD45PerCP 
CD4 PerCP CD3 APC CD3 FITC CD3 FITC 
CD8 PE-Cy7 CD8 PE-Cy7 CD4 APC CD19 APC 
TCR Vbeta PE 
TCR Vbeta PE+FITC 
TCR Vbeta FITC 
CD19 Pacific Blue CD8 PE CD16/56 PE 
CD16 PE   
CD56 PE-Texas Red   
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10. DNA and RNA extraction 
DNA was extracted from whole blood, PB MNCs, or sorted lymphocyte 
populations using Genomic DNA NucleoSpin Tissue kits or Tissue XS kits (when the 
number of cells was <100 000) (Macherey-Nagel). RNA was extracted with Total 
RNA Isolation: NucleoSpin RNA II kits (Macherey-Nagel) or miRNAeasy kits 
(QIAGEN). RNA and DNA concentrations were measured with Nanodrop (Thermo 
Fisher), Qubit 2.0 (Life Technologies), or Agilent 2100 (Agilent Technologies) 
bioanalyzers.  
 
11. Sequencing methods 
11.1. Capillary sequencing 
Primers for capillary sequencing were designed using Primer-Blast search 
(http://blast.ncbi.nlm.nih.gov/). PCR products were either extracted from gels or 
purified from PCR reactions using the QIAquick Gel Extraction Kit (QIAGEN) in 
studies I and III, or the Montage Cleanup Kit (Millipore) in study II. Purified PCR 
products were sequenced with the BigDye v.1.1. Cycle Sequencing kit and an ABI 
PRISM 3730xl DNA Analyzer. Chromatograms were analyzed with ChromasPro 
(Technelysium), 4Peaks (Mek&Tosj), and Sequencher (Gene Codes Corporation). 
All STAT3/STAT5 capillary sequencing primers are presented in Table 4.  
 
Table 4. STAT3 and STAT5 primer sequences. 
Primer use Primer target Sequence (5’-3’) 
STAT3 capillary 
sequencing (Studies I, 
II, IV) 
STAT3 exons 18 and 19 F ATCTCCACCCACCAGGGGGC 
STAT3 exons 18 and 19 R AGGGAAGGGCTGGGATGGCA 
STAT3 exon 20 F TCCCATCGGTCACCCCAACA 
STAT3 exon 20 R GCCAGGCCACTGAACAGGGTG 
STAT3 exon 21 F TCCCATTCCCAGGGATAACTGAGGA 
STAT3 exon 21 R TCCTGCCGAGGCAGATGGCT 
STAT3 exon 22 F AGAGCATCACACAAAGGGGACCA 
STAT3 exon 22 R TCCTGCCGAGGCAGATGGCT 
STAT3 exon 23 F GCAGGTAGGCGCCTCAGTCG 
STAT3 exon 23 R TGCAGAGGGTGGACAACTGAACT 
STAT5A/B capillary 
sequencing (Study III) 
STAT5A exon14 F TCTGTCCCTGCATGCCCCCA 
STAT5A exon14 R GGGGCCCCCATCTCTCCTGG 
STAT5A exon15 16 F GCCCTGACTCGGGGGTTCCT 
STAT5A exon15 16 R GTGGCGGGGCAAGGGAACAA 
STAT5A exon 18 19 F ACATGGGGCGTGGGCTTCCA 
STAT5A exon 18 19 R GCCAGCCCTCCAGGAGTCCA 
STAT5A exon 20 F AGCAGGCTGGAGGCTGTCCC 
STAT5A exon 20 R AGGACTGCACAGGGGAGGCA 
STAT5B exon 14 15 F AGGCGGGGATATTTGTATGCCTCT 
STAT5B exon 14 15 R TGTTCATGTGTAACCATGCTGCCAT 
STAT5B exon 17 18 F AGGTGGTTGTGTTCTGTCCT 
STAT5B exon 17 18 R CAGTTCCTCCCCTGTGGAC 
STAT5B exon 19 F CTGGTGGCCTGTGGGGCTTG 
STAT5B exon 19 R TCTGTCTGTGGCCCCTCTGCT 
STAT3 amplicon 
sequencing (Study 
IV)* 
STAT3 exon 21 amplicon F ACACTCTTTCCCTACACGACGCTCTTCCGATCTCCCAAAAATTAAATGCCAGGA 
STAT3 exon 21 amplicon R AGACGTGTGCTCTTCCGATCTGGTTCCATGATCTTTCCTTCC 
STAT5 amplicon 
sequencing (Study III) 
STAT5A exon 17 amplicon F ACACTCTTTCCCTACACGACGCTCTTCCGATCTTCCTGCTGCTGGTGGATTAT 
STAT5A exon 17 amplicon R AGACGTGTGCTCTTCCGATCTAGCCCAAGGCTTTGTCTATG  
STAT5B exon 16 amplicon F ACACTCTTTCCCTACACGACGCTCTTCCGATCTTGTTGGGGTTTTAAGATTTCC 
STAT5B exon 16 amplicon R AGACGTGTGCTCTTCCGATCTCAAATCAGAATGCGAACATTG 
*Target-specific sequences are underlined in amplicon primers. All amplicon primers contain 
Illumina adapter sequence tails. 
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11.2. Whole-exome sequencing 
Paired samples from each patient were prepared and used for exome sequencing 
in studies I and III: CD8+ cells were used as LGL leukemia samples and CD4+ cells 
as controls. A total amount of 3 µg of each genomic DNA sample was fragmented 
with Covaris S-2 focused-ultrasonicator (Covaris) and processed with NEBNExt 
DNA Sample Prep Master Mix Set (New England Biolabs). Illumina Paired-End (PE) 
PCR primers were used for amplification of the library (Illumina). Exome capture was 
processed using the Agilent SureSelect Target Enrichment System for Illumina 
Paired-End Sequencing Library and SureSelect Human All Exon protocols (Agilent). 
Captured libraries were amplified in post-capture PCR with NimbleGen PE-POST1 
and PE-POST2 primers (Roche). Cluster generation and sequencing of exome 
libraries were performed with Illumina GAII (Study I) or Illumina HiSeq2500 (Study 
III) instruments as 82 bp PE reads (Illumina). 
After sequencing, the data were run through bioinformatics analysis tools. Raw 
reads were trimmed based on the quality scores, which were converted to Sanger 
phred scores of FASTQ files. Reads were then aligned against the current human 
genome build (hg19) with the Burrows-Wheeler Aligner.190 Potential PCR duplicates 
and reads with poor mapping quality were eliminated. SAMtools was used to create 
pileup files (files that describe the base-pair information at every chromosomal 
position) to enable subsequent SNV/indel calling. 
Somatic mutations specific for leukemic sample were called with the VarScan 
2.2.3 or newer somatic mutation caller.192,194 Missense, nonsense, frameshift, inframe 
coding indels, and splice site mutations with a VarScan somatic p-value below 0.01 
were considered to be candidate mutations and their functional consequences were 
analyzed using software such as PolyPhen-2. GERP conservation scores were 
calculated with Annovar to assess the level of conservation of the mutated site in 
evolution.195 Known public variants were excluded using different databases (1000 
Genomes Project Consortium, dbSNP132). Candidate somatic mutations were 
checked visually in the Integrative Genomics Viewer (IGV). Capillary and/or 
amplicon sequencing primers were designed for every candidate mutation to validate 
it from the source DNA with a different method. 
Different tools were used for the prediction of the effects of a mutation. The 
COSMIC database (http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/) is a 
catalogue of somatic mutations in cancer, and it was used to assess whether the same 
mutation has been reported previously in cancer.201 PolyPhen-2 
(http://genetics.bwh.harvard.edu/pph2/) predicts the functional effects of human non-
synonymous single nucleotide variants leading to an amino acid substitution.202 
PolyPhen-2 predictions are based both on the data of the structural conservation of 
amino acid sequence (functionally important residues are highly conserved in 
evolution) and available structural information of the mutated protein.202 
The basic terminology of second-generation sequencing is explained in Figure 6. 
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Figure 6. Basic terminology of second-generation sequencing. 
 
11.3. RNA sequencing 
RNA sequencing was used for gene expression analysis in study I: CD8+ RNA 
was extracted from a T-LGL leukemia patient and a healthy normal donor 
(anonymous Finnish Red Cross buffy coat) CD8+ RNA was used as a control. 
Ribosomal RNA was depleted with Ribo-Zero rRNA Removal Kit (Epicentre) and the 
sample was then reverse-transcribed to cDNA with SuperScript reverse transcriptase 
(SuperScript). The RNA sequencing library was prepared with Nextera technology 
(Epicentre) and amplified with primers containing Illumina adapters. The cluster 
generation and library sequencing (72 bp paired-end reads) were done with Illumina 
GAII.  
RNA-sequencing reads from the index patient and normal control were aligned to 
the human reference genome hg19 using TopHat, which analyzes the mapping results 
to identify splice junctions between exons, and the number of mapped reads were 
counted with HTseq Python package. DEseq R/Bioconductor package was used for 
the analysis of differentially expressed genes, and the resulting gene expression data 
were analyzed with IPA software (Ingenuity). The expression levels of exome 
sequencing somatic variants were checked with IGV. 
 
11.4. Targeted deep STAT3 and STAT5B sequencing 
Amplicon sequencing of STAT3 (exon 21), STAT5A (exon 17) and STAT5B (exon 
16) was used in studies III (STAT3) and IV (STAT5A, STAT5B). Locus-specific 
primers are presented in Table 4. The PCR reaction contained locus-specific PCR 
primers (with Illumina adapter sequence tails), Illumina TruSeq Universal Adapter 
primer, and Illumina TruSeq Adapter primer with a 6 bp index sequence (used for 
genetic barcoding of each sample). This initial amplification creates Illumina-
compatible paired-end sequencing templates. Indexes are used to recognize sample-
specific reads after the pooled sequencing run. Sequencing of PCR amplicons was 
performed using the Illumina MiSeq instrument with MiSeq Control Software 
(Illumina). Samples were sequenced as 151 bp or 251 paired-end reads using MiSeq 
amplicon workflow (Illumina).   
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Data were analyzed with Illumina MiSeq Reporter Software (Illumina) in study 
III. A specifically developed bioinformatics pipeline was used in study IV: first, after 
mapping the reads to STAT3 gene, previously reported STAT3 mutations were verified 
and all variants with a variant allele count over 5 and variant allele frequency (VAF) 
over 0.5% were taken into consideration. Second, a broader manner of approach was 
used, as all variants with variant allele count over 5 and VAF over 0.5% were called, 
and from these variants false positives were initially filtered out based on the 
estimated error rate from control sample in every run (a p-value vas calculated using 
binomial distribution). However, variants with VAF over 2% were called independent 
of the noise. In both scripts, a specific frequency ratio was calculated to filter out false 
positive variants, and all samples with a frequency ratio ≥0.80 were considered to be 
true mutations (Figure 7). The variants from both scripts with a borderline frequency 
ratio between 0.75-0.79 were verified manually with IGV. 
 
 
 
 
Figure 7. Frequency ratio formula of amplicon sequencing analysis pipeline. 
 
11.5. Targeted deep TCRB sequencing 
In study IV, TCRB CDR3 regions were amplified and sequenced by Adaptive 
Biotechnologies Corp (Seattle, WA, US) using the ImmunoSEQ assay. The assay 
used analyzes the TCRB CDR3 repertoire and can detect a rearrangement of one cell 
in 40 000 T cells. Flow cytometry-sorted lymphocytes from three T-LGL leukemia 
patients were sequenced with 52 forward primers for the Vβ gene segment and 13 
reverse primers for the Jβ segment in a multiplex-PCR reaction, to analyze the TCRB 
CDR3 VDJ rearrangement sequence. The resulting 60 bp amplicons were sequenced 
with Illumina HiSeq platform (Illumina). Raw sequences were aligned based on the 
V, D, and J gene definitions of IGMT database. The data were analyzed using 
ImmunoSEQ analyzer provided by Adaptive Biotechnologies. The Simpson’s 
diversity index was calculated for every sample to assess the level of narrowing of T 
cell receptor repertoire (Figure 8). 
 
 
Figure 8. The calculation of Simpson’s diversity index, where ”n” represents the 
observed counts of a particular TCRB rearrangement seen in the sample, whereas 
”N” is the total number of all TCRB rearrangements (amplicon reads) in the sample. 
 
11.6. Other sensitive PCR methods 
In addition to amplicon sequencing, other sensitive sequencing methods were also 
used in the detection of STAT3 mutations. In study II, the presence of the two most 
common STAT3 mutations, D661Y and Y640F, was determined by amplification 
refractory mutation system (ARMS) assay.203 In study IV, real-time allele-specific 
oligonucleotide quantitative PCR (ASO-qPCR) of STAT3 mutations Y640F and 
D661V was performed to compare to amplicon sequencing of STAT3: A Y640F or 
D661V mutation-positive reference sample was used for preparing a log-linear 
the ratio of variant calls/number of all the bases (at a position)
the ratio of variant allele quality sum/quality sum of all the bases (at a position) 0.80
D = 
 n(n-1)
N(N-1)1-
 40 
dilution series, and a standard curve was made based on the ASO-qPCR results. The 
data were normalized with qPCR of albumin reference gene, and the mutation load of 
the samples examined was quantified in relation to the standard curve. 
 
 
12. Functional assays 
12.1. STAT3 and STAT5B mutagenesis 
STAT3 and STAT5B constructs were created for studies I and III, respectively.  
In study I, the starting point was an open-reading frame (ORFeome) clone of the 
human STAT3 gene coding sequence inserted in the pENTR201 vector (NM_003150, 
acquired from the Genome Biology Unit at the University of Helsinki). Vectors 
containing one common STAT3 mutation—Y640F or D661V—were created by site-
directed mutagenesis using 5’-phosphorylated primers presented in Table 5. After 
confirmation of the successful mutagenesis by sequencing, both wild type (wt) and 
mutated STAT3 coding sequences were transferred to a V5-tagged pDEST-40 
mammalian expression vector using Gateway® LR Clonase II enzyme mix (Life 
Technologies). 
In study III, STAT5B mutations Y665F and N642H were introduced to an 
expression plasmid pCMV6-XL6 containing the wild type coding sequence of 
STAT5B (OriGene, SC115355) with the GENEART® Site-Directed Mutagenesis 
System (Invitrogen). The mutations were confirmed by capillary sequencing of the 
plasmid DNA. Mutagenesis primers are listed in Table 5. 
 
Table 5. STAT3 and STAT5B mutagenesis primers. The site of primer mismatch is 
underlined. 
Primer use Primer target Sequence (5’-3’) 
STAT3 mutagenesis (Study I) 
STAT3 Y640F F CTGAACAACATGTCATTTGCTG  
STAT3 Y640F R CTGCTGCTTTGTGAATGGTTCCACGG  
STAT3 D661V F CTGGTGTCTCCACTGGTCTATC  
STAT3 D661V R GATATTGGTAGCAACCATGATCTT  
STAT5B mutagenesis (Study III) 
 
STAT5B Y665F F GAGACTTGAATTTCCTTATCTACGTGTTTC  
STAT5B Y665F R GAAACACGTAGATAAGGAAATTCAAGTCTC   
STAT5B N642H F GAAAGAATGTTTTGGCATCTGATGCCTTTTAC  
STAT5B N642H R AAAGGCATCAGATGCCAAAACATTCTTTC 
 
 
12.2. Western blotting 
Western blotting experiments were mainly conducted on whole cell-lysates or 
from subcellular-fractionated samples (cytosolic and nuclear lysates) from LGL 
leukemia patients: 20 million PB MNCs were first suspended in hypotonic buffer (10 
mM hydroxyethyl piperazineethanesulfonic acid  [HEPES, pH 7.9], 10 mM KCl, 1.5 
mM MgCl2, 0.5 mM dithiothreitol [DTT]), and after swelling, the cells were sheared 
in a pre-cooled homogenizer (Douncer). After centrifuging, supernatants containing 
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the cytosolic fraction were collected, and pellets were centrifuged over a sucrose 
cushion to extract the nuclear fraction, which was subsequently lysed. 
Protein concentrations of whole cell, nuclear, or cytosolic lysates were measured, 
and normalized aliquots of the different fractions were ran on an SDS-PAGE gel (8-
15%) and subsequently transferred to a PVDF membrane (Bio-Rad). The membranes 
were blocked with 5% BSA or 5% fat-free milk and then incubated with primary 
antibodies. In study I, the following primary antibodies were used: rabbit anti-Erk1 
(Santa Cruz sc-94) 1:1000, rabbit anti-phosphoY705 STAT3 (Cell signaling, #9145) 
1:2000, or mouse anti-STAT3 (Cell Signaling, #9139) 1:1000. Primary antibodies of 
study III were rabbit anti-phosphoY694 STAT5B (Cell Signaling, #9351) 1:500, rabbit 
anti-STAT5 (Cell Signaling, #9358), rabbit anti-phosphoY705 STAT3 (Cell Signaling 
9145) 1:2000, mouse anti-STAT3 (Cell Signaling, #9139) 1:1000, or mouse anti-
GAPDH (Novus Biologicals 300-285) 1:5000. After ligation of appropriate secondary 
antibodies (containing infrared-readable dyes), protein bands were visualized with the 
LI-COR Odyssey (LI-COR). 
 
 
12.3. Enzyme-linked immunosorbent assay (ELISA) 
The total and phosphorylated STAT5 protein was analyzed by ELISA in study III 
using PhosphoTracer STAT5A/B pTyr694/699+Total ELISA Kit (Abcam). 
Mononuclear cells were lysed with kit reagents. Prior to analysis, protein 
concentrations were measured with the Qubit 2.0 fluorometer (Life Technologies) to 
ensure that the concentrations were similar between samples. The analysis was done 
in duplicate. PHERAstar FS reader (BMG Labtech) was used to measure fluorescence 
intensity. 
 
12.4. Immunohistochemistry 
Immunohistochemistry in study I was performed using a Leica BOND-MAX 
autostainer (Leica Microsystems, Wetzlar, Germany). Slides were prepared from 
FFPE tumor and healthy control bone marrow biopsy blocks. After baking, the slides 
were handled with a Bond Polymer Refine Detection kit (Leica Microsystems) 
including citrate buffer for antigen retrieval, and stained with monoclonal anti-
phospo-STAT3Y705 antibody (9145, Cell Signaling Technology, Danvers, MA, US) 
1:100 or anti-CD57 antibody (TB01, Dako, Glostrup, Germany) 1:100. The slides 
were visualized with the Zeiss Axio Imager AX10 microscope (Zeiss) and 
photographed with Nuance FX multispectral tissue imaging system (PerkinElmer). 
 
12.5. STAT3 and STAT5B reporter assay 
In study I, HEK293 cells stably expressing the GloResponse SIE-Luc2P luciferase 
reporter (Promega) were transfected with empty pDEST-40 or STAT3-containing 
pDEST-40 vectors using lipofectamine-assisted transfection. On the next day, the 
cells were mock-treated or stimulated with IL-6, and Dual-Glo luciferase detection 
reagent (Promega) was used to analyze firefly luciferase activity.  
In study III, HeLa cells were transiently transfected using lipofectamine with 
pCMV6-XL6 vector containing STAT5B and another vector with Luc2P-luciferase 
reporter sequence under the control of STAT5 response element (pGL4.52 vector 
with Luc2P/STAT5RE/Hygro, Promega). On the following day, unstimulated firefly 
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luciferase activity was measured with One-Glo luciferase detection reagent 
(Promega). 
 
13. Gene expression analysis 
13.1. Illumina gene expression array 
In study I, CD8+ cells from T-LGL leukemia patients with/without STAT3 
mutations were compared with healthy control CD8+ cells using Illumina Human 
HT-12 v4 Expression BeadChip array (Illumina). After hybridization, microarrays 
were read with a BeadArray Reader (Illumina) and analyzed with GeneSpring GX 
software (Agilent Technologies): samples were first transformed logarithmically by 
scaling to median baseline intensity of each chip, and then normalized.  
In study III, the comparison was done between 3 STAT5B-mutated patients with 
LGL leukemia, 3 STAT3-mutated patients, 2 STAT3- and STAT5A/B-unmutated 
patients (unmutated by exome sequencing), and 4 healthy controls (2 CD8+ and 2 NK 
cell samples). An Illumina Human HT-12 v4 Expression BeadChip array (lllumina) 
was used for gene expression analysis. The chips were read with an iScan instrument 
(Illumina), followed by primary analysis with Genome Studio software (Illumina). 
Normalization and analysis of data were done with Chipster software (version 2.10): 
data were normalized and log2-transformed. Expression profiles were compared with 
pairwise Pearson correlation. Differentially expressed genes were detected with 
empirical Bayes test. Pathway analysis was performed with KEGG and 
hypergeometric test. The microarray data were uploaded into the open-access 
ArrayExpress database under accession number E-MTAB-1611. 
 
14. Statistical methods 
In study I, PASW Statistics software (version 18.0) was used to calculate clinical 
correlations of STAT3 mutations, using Fisher’s exact and unpaired 2-sided t-tests 
(p<0.05 considered statistically significant). In study II, with a larger patient cohort, 
overall survival and progression-free survival related to mutation status were also 
analyzed with the Kaplan-Meier and Cox methods. In study IV, GraphPad Prism 
software (version 5.0) was used to analyze clinical data: a chi-square test was used 
when categorical variants were compared, whereas either a 1 way ANOVA with 
Bonferroni post hoc test or an unpaired t test was used for parametric variables. 
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RESULTS  
15. Exome sequencing of T-LGL leukemia patients (I, III) 
The analysis of the molecular background of LGL leukemia started with exome 
sequencing of LGL leukemia patients. The aim was to discover novel somatic genetic 
variants related to the pathogenesis of the disease. The patients chosen fulfilled the 
diagnostic criteria of LGL leukemia by WHO 20089, were untreated, and had a large 
monoclonal expansion in CD8+ T cell fraction.  
 
15.1. Exome sequencing results of the index T-LGL leukemia patient (I) 
The index patient was a male and 71 years old at the time of the exome 
sequencing. Clinical characteristics of the patient are presented in Table 6. The 
diagnosis of LGL leukemia was based on persistent PB lymphocytosis, clonal TCR 
rearrangement, and chronic neutropenia; however, no severe infections were seen 
during follow-up. The Vbeta analysis of CD8+ fraction revealed one Vb16+ 
immunodominant expansion at all timepoints (Figure 9). Vbeta results of the CD4+ 
fraction were polyclonal (data not shown). The size of the Vb16+ clone was 94% of 
CD8+ cells at the time of the exome sequencing (Figure 9). During follow-up, the size 
of the clone diminished and at the same time, a decrease in lymphocyte counts and 
improvement of neutropenia was observed (Figure 9).  
 
Table 6. Clinical characteristics of the three exome sequenced patients. All 
laboratory values are presented as medians and range.  
Patient Age 
at dg 
Gender Follow-
up time 
Hb, 
g/l1 
Leuk, 
x109/L 
Lymph, 
x109/L 
Neut, 
x109/L 
Plts, 
x109/L 
Phenotype Associated 
disorders 
1  
(Study 1) 
70 Male 60 
months 
123 
(87-
160) 
9.0 
(4.8-
23.2) 
3.7 (1.7-
14.0) 
1.6 
(0.6-
7.6) 
311 
(164-
594) 
CD8+ 
TCRα/β+ 
Neutropenia 
2  
(Study 
III) 
71 Female 40 
months 
126 
(102-
133) 
11.8 
(8.5-
18.2) 
8.3 (5.8-
11.7) 
4.2 
(3.0-
5.5) 
249 
(156-
287) 
CD8+ 
CD56+ 
TCRα/β+ 
RA-like 
symptoms 
3  
(Study 
III) 
49 Female 36 
months 
126 
(120-
132) 
16.9 
(13.2-
19.7) 
13.4 
(10.2-
15.4) 
2.5 
(1.15-
3.44) 
279 
(260-
301) 
CD8+ 
CD56+ 
TCRα/β+ 
None 
1All laboratory values are presented as medians and range during follow-up time. 
Abbreviations: dg, diagnosis; Hb, hemoglobin; Leuk, leukocytes; Lymph, lymphocytes; Plts, 
platelets; RA, rheumatoid arthritis 
 
 
Figure 9. TCR Vbeta results (CD8+ lymphocytes) of the patient 1 in study I (Table 6). 
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Exome sequencing of patient 1 was done from the magnetic bead-sorted CD8+ 
fraction and CD4+ cells were used as a control. The exome sequencing produced 60.2 
million (CD8+) and 61.1 million (CD4+) reads, which were aligned to the reference 
genome. The early version of the variant calling pipeline did not calculate the median 
coverage, but 59% and 62% of the exons in CD8+ and CD4+ samples, respectively, 
were sequenced with depth more than x20.  
Exome sequencing pipeline and somatic mutation calling are described in the 
methods section (Chapter 11). Briefly, Varscan was used to call somatic mutations 
specific for CD8+ fraction. Candidate mutations (somatic p<0.01) were taken into 
consideration, and their functional effects were inspected using PolyPhen-2 and other 
annotation software. Known population variants were excluded using the data from 
the 1000 Genomes Project Consortium and dbSNP132. Plausible variants with 
connection to the immune system or cancer were taken into further consideration and 
were checked visually using the IGV. The expression of the variants was verified 
from RNA sequencing data. Capillary and/or amplicon sequencing primers were 
designed for every candidate mutation to validate it from the source DNA with a 
different method. 
After comparison of CD8+ and CD4+ samples, seven variants were chosen for 
capillary sequencing validation, and 4/7 of these variants were confirmed specific for 
CD8+ sample (Table 7). The mutated genes included calpain 13 (CAPN13), 
homeobox C9 (HOXC9), macrophage scavenger receptor 1 (MSR1), and signal 
transducer and activator of transcription 3 (STAT3). Of these, STAT3 mutation D661V 
was the only one expressed in the RNA sequencing data. 
 
Table 7. Exome sequencing somatic variants of patient 1 (Table 6), CD8+ fraction 
Gene Chr Posit Mutations type Protein 
Ref. 
base 
Var. 
base 
CD8 
ref 
(n) 
CD8 
var 
(n) 
CD4 
ref 
(n) 
CD4 
var 
(n) 
Somatic p 
1 
RNA-
seq. 2 
CAPN13 2 30966280 Nonsense R472* G A 92 65 168 2 2.94x10-22 NE 
HOXC9 12 54396263 Frameshift NA T delT 25 9 38 0 0.00062 NE 
MSR1 8 50692579 Missense R26C G A 11 8 28 0 0.00024 0/1 
STAT3 17 118219358 Missense D661V T A 39 28 63 0 2.66x10-10 119/295 
Abbreviations: chr, chromosome; del, deletion; NA, not accessible; NE, not expressed; Ref, reference; 
Var, variant. 
1Somatic p-value for somatic/loss-of-heterozygosity events: significance of tumor read count vs. normal 
read count 
2Number of variant alleles/total sequencing depth in RNA sequencing data.  
 
CAPN13 is a member of the calpain protein family. Calpains are intracellular 
Ca2+-dependent proteases that cleave their substrates at specific inter-domain sites, 
affecting several signaling cascades connected to cell growth and survival.204 The 
mutation of patient 1 in CAPN13 introduced a stop codon at amino acid R472. The 
mutation leads to translation of a truncated protein lacking the EF-hand domain, thus 
possibly impairing the calcium-binding ability of the mutated CAPN13. However, the 
exon with the mutation was not expressed in RNA sequencing. 
HOXC9 and other homeobox genes regulate transcription, are involved in 
development, and their aberrant expression is associated with cancer.205 The 
frameshift mutation of patient 1 occurred at the beginning of the DNA-binding 
homeodomain of HOXC9 (after amino acid K195), and could impair the 
transcriptional activity of HOXC9. The mutated spot was not expressed in the RNA 
sequencing data. 
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MSR1, known also as SR-A, is important in the innate immune system as it is 
expressed on the surface of macrophages, where it recognizes pathogens and modified 
self-proteins such as lipids.206 The COSMIC database reports the same missense 
mutation, R26C, in a carcinoma of the large intestine, and sporadic mutations of 
adjacent amino acids have been reported in breast and endometrium carcinomas. 
PolyPhen-2 predicted the R26C mutation to be probably damaging, and amino acid 
R26 is highly conserved in evolution. The mutation was not expressed in the RNA 
sequencing. 
The function of the normal STAT3 protein is reviewed in the first section of this 
thesis (Chapter 5). The D661V mutation was in the SH2 domain, which is important 
for the dimerization of STAT3. Based on the PolyPhen-2 report, the mutation was 
probably damaging and situated in a highly conserved area. Amino acid D661 is in a 
SH2 domain surface loop, which comes to close proximity of the other STAT3 
monomer during dimerization.112 
 
15.2. STAT3 sequencing of the index T-LGL leukemia patient (I) 
STAT3 D661V mutation of the patient 1 (Table 6) was the most interesting of four 
somatic mutations detected (Table 7). To analyze the location of the mutation, 
different lymphocyte fractions were sorted with flow cytometry from a PB MNC 
sample. The gating strategy is shown in Figure 10. The mutation was confirmed 
specific for CD8+ fraction by capillary sequencing (Figure 10). Vb16+ clone 
consisted of 94% of the CD8+ fraction, and both exome sequencing (Table 7) and 
capillary sequencing suggested that mutation was heterozygous in the leukemic 
Vb16+ population. 
 
 
 
 
Figure 10. Lymphocyte fractions and STAT3 capillary sequencing results of patient 1 
in study I (Table 6). CD4+/CD8+ and CD16/56+/CD19+ cells were sorted from 
different tubes. 85% of CD3+ lymphocytes were CD8+, and the STAT3 mutation 
D661V was seen only in CD8+ fraction. 
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15.3. Exome sequencing results of STAT3 mutation-negative T-LGL leukemia 
patients (III) 
Two STAT3-mutation negative patients were chosen for exome sequencing in 
study III. The clinical characteristics of patients 2 and 3 are presented in Table 6. The 
Vbeta analysis of patient 2 (Table 6) was done once, and 91% of the CD8+ cells were 
major Vb22+ expansion (Figure 11A). Patient 3 (Table 6) had also large clone: 
Vb17+ cells consisted of 94% of the CD8+ fraction at two separate timepoints (Figure 
11B-C).  
 
 
 
Figure 11. TCR Vbeta results of patients 2 (A) and 3 (B-C) (Table 6) in study III. (A) 
CD8+ Vbeta results of patient 2 one year after the diagnosis. CD8+ Vbeta expression 
of patient 3 was analyzed one (B) and two (C) years after the diagnosis. 
 
Similar to patient 1 (Table 6), a CD8+ fraction was used as a tumor and CD4+ 
cells as a control in exome sequencing. In the case of patient 2 (Table 6), sequencing 
yielded 62 million and 64 million aligned reads for CD8+ and CD4+ samples, 
respectively. The median coverage was not analyzed, but 54% (CD8+) and 55% 
(CD4+) of the target exons were sequenced with more than x20 coverage. In the case 
of patient 3, the number of aligned reads was 68 million (CD8+) and 53 million 
(CD4+), and more than x20 coverage was achieved in 55% and 52% of target bases, 
respectively. 
Somatic variants with p<0.01 were validated with capillary sequencing. Of the 
four variants of patient 2 (Table 6), two were confirmed to be specific for CD8+ 
fraction by capillary sequencing, and the mutations were located in bone marrow 
morphogenetic receptor 2 (BMPR2) and STAT5B (Table 8). The capillary sequencing 
of patient 3 (Table 6) validated 3 of 4 candidate mutations in following genes: early B 
cell factor (EBF3), sphingomyelin synthase 2 (SGMS2), and STAT5B (Table 9). 
Thus, both patients carried the same Y665F mutation in the STAT5B gene, and in both 
cases this mutation was expressed in the RNA sequencing data (Tables 8 and 9).  
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Table 8.  Exome sequencing somatic variants of patient 2 (Table 6), CD8+ sample.  
Gene Chr Posit Mutation type Protein 
Ref. 
base 
Var. 
base 
CD8 
ref 
(n) 
CD8 
var 
(n) 
CD4 
ref 
(n) 
CD4 
var 
(n) 
Somatic p 1 
RNA
-seq. 
2 
BMPR2 2 203379664 Missense E195K G A 39 42 113 1 7.10x10-19 13/25 
STAT5B 17 40359659 Missense Y665F T A 43 30 99 0 9.34x10-14 73/171 
Abbreviations: chr, chromosome; del, deletion; NA, not accessible; NE, not expressed Ref, reference; 
Var, variant 
1Somatic p-value for somatic/loss-of-heterozygosity events: significance of tumor read count vs. normal 
read count 
2Number of variant alleles/total sequencing depth in RNA sequencing data.  
 
Table 9. Exome sequencing somatic variants of patient 3 (Table 6), CD8+ sample. 
Gene Chr Posit Mutation type Protein 
Ref. 
base 
Var. 
base 
CD8 
ref 
(n) 
CD8 
var 
(n) 
CD4 
ref 
(n) 
CD4 
var 
(n) 
Somatic p 1 
RNA
-seq. 
2 
EBF3 10 131761204 Splice-5 NA A G 73 41 93 0 4.42x10-13 NE 
SGMS2 4 108820744 Missense R157C C T 123 89 212 0 1.20x10-32 0/1 
STAT5B 17 40359659 Missense Y665F T A 38 41 63 0 5.98x10-14 149/343 
Abbreviations: see Table 8. 
 
 
Patient 2 (Table 6) had a CD8-specific mutation in the BMPR2 gene, which 
belongs to the receptor family of serine/threonine kinases. BMPR2 loss-of-function 
mutations have been detected in pulmonary hypertension patients.207 The mutated 
amino acid E195 was conserved in the BMPR2 gene of vertebrates and was estimated 
to be probably damaging by PolyPhen-2. The location of the mutation was near the 
kinase domain and the ATP-binding site of BMPR2. Two sporadic cases of 
endometrial and large intestine cancer were reported by the COSMIC database to 
carry the same mutation. The mutation was expressed in the RNA sequencing. 
STAT5B, which was mutated in both patients 2 and 3, is reviewed in Chapter 5 of 
this thesis. Similar to the STAT3 D661V mutation of patient 1, STAT5B Y665F was 
also located in the SH2 domain. PolyPhen-2 reported the mutation as benign, and the 
area was conserved in mammals. COSMIC did not report mutations in Y665, 
although missense mutations in nearby residues have been detected in kidney and 
lung carcinoma. The mutation was expressed in the RNA sequencing. 
The remaining mutations of patient 3 (Table 6) included a splice-5 site mutation in 
EBF3. EBF3 is a member of EBF family of transcription factors, which mediate B 
cell, bone, and neuronal differentiation and development, and act as tumor-
suppressors: silencing mutations of EBF3 are frequently observed in glioblastoma.207 
A splice-site mutation could potentially be a loss-of-function variant, as it affects the 
splicing of the pre-messenger RNA and subsequent translation of the functional EBF3 
protein.  
SGMS2 catalyzes the production of sphingomyelin, which is a major component 
of cell membrane. SGMS2 activity affects the cell surface composition and formation 
of lipid rafts, which harbor cell surface receptors.208 Considering the connection to 
cancer, sphingomyelins were downregulated in the glioma cell line and activation of 
SGMS caused an increase in sphingomyelin levels with simultaneous apoptosis of 
glioma cells.209 Amino acid R157 is located in a loop between two transmembrane-
regions, and no mutations are reported in this residue. PolyPhen-2 predicted the 
mutation to be probably damaging and located in a conserved area.  
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16. Results of STAT3 and STAT5B mutation screening in LGL 
leukemia patients (I-IV) 
Amplicon sequencing and/or capillary sequencing were used in the screening of 
STAT3 and STAT5B mutations in exons 21 and 16, respectively, and other SH2 
domain exons of STAT3 and STAT5B genes were sequenced with capillary 
sequencing. In the following section, the screening results of recurrent STAT3 and 
STAT5B mutations are presented.  
The primers were also designed for the capillary sequencing validation of the 
other exome sequencing variants than STAT3/STAT5B mutations (Tables 7-9) of 
patients 1-3. These mutations proved to be non-recurrent in the patient cohorts. 
 
16.1. STAT3 screening by capillary sequencing in LGL leukemia (I, II, IV) 
The most promising CD8-specific variant of patient 1 (Table 7), STAT3 D661V, 
was screened first from the cohort of 8 Finnish T-LGL leukemia patients with 
monoclonal disease (patients included in study I). Among these patients, 3 of 8 
harbored a STAT3 mutation in exon 21 of STAT3 gene. Recurrent STAT3 mutations 
led to the initiation of study I, in which the exons 18-23 of SH2 domain of STAT3 
were sequenced by capillary sequencing from a cohort of 77 T-LGL leukemia 
patients, including patient 1 (Table 6). The samples were either whole blood or PB 
MNC DNA. To ensure that the sensitivity of capillary sequencing would be sufficient 
to detect mutations, the whole blood patient samples chosen for screening had a 
monoclonal expansion in Vbeta analysis (data available from 41/77 patients, median 
Vbeta size 83% of CD8+ cells, range 32-99%). The remaining samples were PB 
MNC DNA, and the assumption was that the sensitivity of capillary sequencing 
would be sufficient to detect mutations. 
The frequency of STAT3 mutations in the study I cohort was 40% (31 of 77 
patients sequenced) (Figure 12). The mutations were focused in two amino acids 
coded by exon 21, Y640 and D661, which accounted for 90% (28/31) of all 
mutations. None of the mutations was either reported by two datasets describing 
genetic variants in population (1000 genomes and dbSNP database) or detected in 
CML patients with reactive LGL lymphocytosis (n=6), AML patients (n=9), ALL 
patients (n=6), or in two T-ALL cells lines (Jurkat, MOLT-4).  
 
 
 
Figure 12. STAT3 mutations in the T-
LGL leukemia cohort of study I. 
Numbers after the mutations indicate 
the amount of patients in each group. 
Two patients had two STAT3 mutations 
(Y640F+D661Y, D661V+N647I). 
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Study I included only T-LGL leukemia patients, and the aim of study II was to 
analyze the frequency of STAT3 mutations in a larger cohort containing both patients 
with T-LGL leukemia (n=120) and CLPD-NK (n=50). The frequency of STAT3 
mutations, determined by a combination of capillary sequencing (exons 18-23) and 
ARMS-PCR assay (Y640F and D661Y variants), was 28% (33/120) and 30% (15/50) 
in T-LGL and CLPD-NK, respectively (Figure 13). One T-LGL leukemia patient 
harbored two different STAT3 mutations (Y640F+D661Y) (Figure 13). Similar to 
study I, mutations in Y640 and D661 were the most common and consisted of 80% of 
the variants detected: in ARMS-PCR assay designed for these mutants additional 7 
STAT3-mutated cases were identified. The STAT3 mutations in study I were seen in 
exon 21, and two additional variants, S614R and G618R, which were coded by 
adjacent exon 20, were detected in study II. The SH2 domains of STAT family 
members (STAT1, STAT2, STAT4, STAT5A, STAT5B, STAT6) were screened in 
addition to other JAK-STAT pathway hotspots, which are frequently mutated in 
cancer (IL6ST exon 6, JAK2 V617F, JAK3 exons 13-17), using samples from 40 
STAT3 mutation-negative LGL leukemia patients, but no mutations were seen in these 
genes. No STAT3 mutations were detected in a cohort of 31 patients with idiopathic 
neutropenia failing to meet complete diagnostic criteria of LGL leukemia. 
The results of study II showed that STAT3 mutations occurred in T-LGL leukemia 
and CLPD-NK with equal frequency. Study II included also two patients with a rarer 
TCR-γδ LGL leukemia, one of which had a STAT3 mutation.  
 
 
 
 
Figure 13. STAT3 mutations in T-LGL leukemia and CLPD-NK patients in study II. 
Numbers after the mutations indicate the number of patients in each group. 
 
16.2. STAT3 screening by amplicon sequencing in LGL leukemia (IV) 
LGL leukemia is a heterogenous disease. The size of the mutated clone in T-LGL 
leukemia can vary and some patients have multiple CD8+ clones in Vbeta analysis.72 
In CLPD-NK, the analysis of the existence and size of LGL clones is challenging, as 
good clonal markers do not exist. Deep amplicon sequencing is a novel method with 
high sensitivity and ability to quantitatively analyze the sizes of the mutated clones. It 
detects all variants in the target area, whereas ARMS-PCR and ASO-qPCR are 
restricted to the use of mutation-specific primers. 
The study IV patient cohort was the largest among the studies of this thesis, and it 
included 174 T-LGL leukemia and 39 CLPD-NK patients, who all met the criteria for 
Y640F (13) 
D661Y (11) 
D661V (3) 
N647I (1) 
K658M (1) 
S614R (3) 
Y640F+D661Y (1) No STAT3 mutations (87) 
Y640F (4) 
D661Y (7) 
D661I (1) 
N647I (2) 
G618R (1) 
No STAT3 mutations (35) 
T-LGL (n=120) CLPD-NK (n=50)
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LGL leukemia diagnosis. However, the T-LGL leukemia cohort included also cases 
with smaller CD8+ clones, which were excluded from the monoclonal T-LGL 
population of study I. Amplicon sequencing samples were either PB MNC DNA or 
whole blood DNA. 
The frequency of STAT3 mutations in exon 21 by amplicon sequencing was 43% 
(75/174) and 18% (7/39) in T-LGL leukemia and CLPD-NK patients, respectively. In 
total, 82 of 213 (38%) patients carried a STAT3 mutation by amplicon sequencing 
(Figure 14), whereas capillary sequencing was able to recognize mutations only in 
23% (49/213) of the cases. Notably, among the patients of study I with large 
immunodominant clones, the frequency of mutations was 63% (45/72) by amplicon 
sequencing.  
STAT3 screening revealed that a surprisingly high number, 22% (18/82), of 
mutated patients had multiple mutations in the STAT3 exon 21 (Figure 14, Table 10). 
The mutations were either in different clones (n=14) or in the same clone (n=4), in 
which case 2 of 4 patients harbored two single SNVs in one codon resulting in one 
amino acid change (Table 10). In agreement with previous publications describing T-
LGL leukemia patients with smaller expansions in addition to the large 
immunodominant clone72, 8 of 14 patients with multiple mutated clones had one 
dominant SNV with bigger variant allele frequency (VAF), accompanied by one or 
multiple low-frequency SNVs (Table 10). 
 
 
Figure 14. STAT3 mutations detected by amplicon sequencing in the study IV cohort. 
Different patterns of multiple mutations are presented in the small pie. Numbers in 
parenthesis indicate the amount of patients in each group. 
 
 
Table 10. Different examples of patients with multiple STAT3 mutations in the same 
or different lymphocyte clones (study IV). 
Patient  VAF1 Variant 1 VAF2 Variant 2 VAF3 Variant 3 VAF4 Variant 4 
Example A 18% 2 SNVs 
make 
D661Y 
      
Example B 36%, 
36% 
N647I, 
D661V 
      
Example C 13% D661Y 3% Y640F 3% N647I 1% I659L 
Example D 3% Y640F 2% D661Y 1% I659L 1% D661V 
Example E 39% Y640F 2% I659L     
Example F 2% K658R 2% Y640F     
Abbreviations: SNV, single nucleotide variant; VAF, variant allele frequency. 
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I659L (1) K658N (1) 
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No STAT3 
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2 STAT3 mutations in the same codon, 
one amino acid change (2)  
2 STAT3 mutations in the same clone (2) 
4 STAT3 mutations in different clones (3) 
2 STAT3 mutations in different clones (11) 
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16.3. Amplicon sequencing sensitivity and reliability (IV) 
In a comparison of amplicon sequencing and ASO-qPCR data of two common 
STAT3 mutants, Y640F and D661V, the results were congruent in 8 of 9 cases: one 
patient was weakly positive for Y640F mutation by ASO-qPCR, but even sorted 
lymphocyte subpopulations appeared unmutated by amplicon sequencing, indicating 
that either the mutated clone was under the detection limit of amplicon sequencing, or 
the Y640F mutation in ASO-qPCR was false positive.  
A dilution series of a sample with STAT3 D661V (VAF 37%) and Y640F (VAF 
1.4%) was sequenced with an amplicon platform (Table 11). The analysis pipeline 
does not filter low quality reads prior to alignment, but uses quality values (QV, i.e. 
Phred scores) to exlude low quality calls. Low average QVs (under 20) are considered 
as errors. The D661V mutation was under the detection limit with the dilution of 
1:100, at which point the number of error calls with low QV probably interfered with 
the detection of the variant. The Y640F mutation with lower VAF was detected with 
the dilution of 1:2. Based on the results, the variants with VAF over 0.5% and 
frequency ratio over 0.80 (borderline 0.75-0.80 checked manually) were considered 
true positives in amplicon analyses (Table 11).  
The screening of STAT3 mutations in the study IV cohort was also a test of 
amplicon sequencing sensitivity. The sequencing depth and VAFs are shown in Table 
12. Amplicon sequencing had superior sensitivity when compared to capillary 
sequencing: the median VAF in samples, which were positive by amplicon but 
negative by capillary sequencing, was 3%, whereas in all amplicon-positive samples it 
was 17% (Table 12). Considering the possibility of false negative results, the median 
number of mapped reads was lower in STAT3 mutation-negative samples (14196 vs. 
6931), and it is theoretically possible that some of these samples are false negatives 
and harbor small mutated clones (Table 12). Finally, the DNA source material could 
also affect the detection threshold of mutation: the median VAF in PB MNC samples 
was naturally higher than in whole blood samples (24% vs 10%, Table 12). However, 
the frequency of STAT3 mutations was similar in PB MNC (39%) and whole blood 
(40%) DNA samples. 
 
Table 11. Allele frequencies and quality values from STAT3 amplicon sequencing 
analysis of dilution series made from a T-LGL sample with STAT3 D661V 
(chr17:40474419 T>A) and Y640F (chr17:40474482 T>A) mutations (study IV). 
Frequency ratio under 0.8 and QVs under 20 are marked in gray. 
Mut
atio
n 
Dilutio
n 
Freq
ratio
1 
Total 
depth2 
T T, 
QV3 
A A, 
QV3 
G G, 
QV3 
C C, 
QV3 
N N, 
QV3 
D
66
1V
  
1:1 1,01 11878 56,5% 35 37,3% 33 1,0% 17 0,7% 15 4,5% 2 
1:2 1,01 5497 78,0% 35 16,6% 34 0,8% 15 0,3% 14 4,3% 2 
1:20 0,95 8132 93,6% 36 1,6% 32 0,4% 16 0,2% 17 4,2% 2 
1:50 0,90 35526 94,3% 36 0,6% 31 0,4% 17 0,2% 16 4,4% 2 
1:100 0,79 26770 94,5% 36 0,4% 27 0,4% 17 0,2% 16 4,4% 2 
Y
64
0F
  
1:1 0,98 15787 97,7% 36 1,4% 35 0,6% 18 0,3% 17 0,1% 2 
1:2 0,86 7207 98,5% 35 0,6% 30 0,6% 18 0,3% 16 0,0% 2 
1:20 0,71 10643 99,0% 36 0,3% 25 0,5% 19 0,2% 16 0,0% 2 
1:50 0,53 46134 98,9% 36 0,2% 19 0,5% 18 0,3% 17 0,0% 2 
1:100 0,55 34932 99,0% 36 0,2% 19 0,4% 18 0,3% 17 0,1% 2 
Abbreviations: Freq, frequency; N, unrecognized base; QV, quality value  
1The calculation of frequency ratio is explained in the Methods section of this manuscript. 
2Number of reads mapped to STAT3 exon 21. 
3The average QV (Phred score) of bases: a non-negative QV is assigned to each called base using a 
logged transformation of the error probability. For example, a QV of 30 means that the error 
probability is 0.1%, whereas a QV of 20 equals 1% error rate. A base with QV under 20 is widely 
considered a sequencing error. 
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Table 12. Amplicon sequencing coverage and VAF of STAT3 mutations of study IV 
(VAF of the largest variant was used in the analysis in case of multiple mutations). 
 All mapped reads, median  
range)1 
Total coverage at the variant 
allele location2 
VAF, median 
(range) 
Positive by capillary sequencing (n=49) 14472 (840-565170) 4060 (264-94038) 27% (5-51) 
Positive only by amplicon sequencing 
(n=32) 
12616 (1255-309580) 5281 (395-21839) 3% (0.6-25) 
All amplicon sequencing positive samples 
(n=82) 
14196 (840-565170) 4103 (264-94038) 17% (0.6-51) 
All amplicon sequencing-negative 
samples (n=131) 
6931 (1270-804232) NA NA 
Whole blood DNA samples, amplicon 
positive (n=35) 
7524 (983-29824) 3638 (488-20873) 10% (0.7-49%) 
PB MNC DNA samples, amplicon 
positive (n=36)  
20427 (840-565170) 3948 (264-11815) 24% (0.6-48%) 
1,2The concepts of mapped reads and coverage are explained in the Methods section, Figure 6. 
Abbreviations: NA, not applicable; VAF, variant allele frequency. 
 
16.4. STAT5B screening by capillary and amplicon sequencing in LGL leukemia 
patient cohort (III) 
The exome sequencing of two STAT3 mutation-negative patients (patients 2 and 3, 
Table 6) identified a novel STAT5B Y665F mutation, and similar to STAT3 mutations, 
the discovery led to the sequencing of additional LGL leukemia patients to see if 
STAT5B mutations were recurrent. The screening of STAT5B SH2 domain mutations 
utilized the combination of amplicon (exon 16) and capillary (exons 14-15 and 17-18) 
sequencing methods, and the patient cohort of study III consisted of 171 T-LGL 
leukemia and 38 CLPD-NK patients.  
Amplicon sequencing reported two additional STAT5B-mutated LGL leukemia 
patients, both of whom carried the N642H mutation in exon 16 of STAT5B gene. 
Thus, the total frequency of STAT5B mutations was 2% (4/211). No mutations were 
detected either in other exons of the STAT5B SH2 domain, or in corresponding areas 
of the STAT5A gene screened (exon 17 by amplicon sequencing). 
The two patients with N642H mutations had abnormal clinical pictures and 
phenotypes: the disease presented with an untypically aggressive, fatal, and treatment-
resistant form in both cases. Clinical characteristics of the patients with N642H 
mutations are presented in Table 13, and similar data for the two patients harboring 
Y665F are in Table 6. 
 
Table 13. Clinical characteristics of the two patients with STAT5B N642H mutation 
Patient 
Age 
at 
dg 
Gender Hb, g/l1 
Leuk, 
x109/L 
Lymph, 
x109/L 
Neut, 
x109/L 
Plts, 
x109/L Phenotype 
Associated 
disorders 
4 
(Study III) 
74 Male 122 90 85.5 0.2 280 CD3+ 
CD56+ 
Splenomegaly, 
lymphadenopathy, 
neutropenia 
5 
(Study III) 
75 Male 168 164.7 131.8 3.3 167 CD3neg 
CD56+ 
Neutropenia, 
hemolytic anemia, 
splenomegaly 
1Laboratory values presented are taken at diagnosis. 
Abbreviations: dg, diagnosis; Hb, hemoglobin; Leuk, leukocytes; Lymph, lymphocytes; Neut, 
neutrophils; Plts, platelets. 
 
Lymphocyte fractions were sorted from all four patients with STAT5B mutation to 
assess the exact location of mutation. The analysis of mutation load in lymphocyte 
subpopulations was done with capillary sequencing (patients 2 and 3, Table 6) or by 
amplicon sequencing (patients 4 and 5, Table 13). The results are presented in Figures 
15–18. 
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In the capillary sequencing of sorted fractions from patient 2 (Table 6), STAT5B 
Y665F mutation was specific for CD8+CD56+ leukemic cells, whereas 
CD3negCD16+CD56+ NK cells were unmutated (Figure 15). The CD4+ fraction was 
unmutated in the exome sequencing analysis (Table 8). The amount of DNA extracted 
from CD3negCD19+ B cells was too low for capillary sequencing. 
 
  
 
Figure 15. STAT5B amplicon sequencing results of patient 2 (Table 6), who had 
CD8+CD56+ T-LGL leukemia (study III). Abbreviations: Chr, chromosome; Freq, 
frequency; Posit, position; Ref, reference; Var, variant. 
 
A similar sorting and sequencing strategy was utilized for the PB MNC sample of 
patient 3 (Table 6). The majority of CD8+ lymphocytes expressed CD56 (Figure 16). 
Leukemic CD8+CD56+ cells were positive for STAT5B Y665F (VAF 48%), and in 
addition, the mutation was seen in CD3neg cells with VAF of 18% (Figure 16). 
However, 30% of CD3neg cells expressed aberrantly CD8 and CD56, and thus Y665F-
mutated cells in CD3neg fraction could be part of the leukemic clone lacking surface 
CD3 expression. CD4+ fraction was unmutated (exome sequencing results, Table 9), 
as were B cells (data not shown). 
 
  
 
Figure 16. STAT5B amplicon sequencing results of patient 3 (Table 6), who had 
CD8+CD56+ T-LGL leukemia (study III). Abbreviations: see Figure 15. 
CD3 APC-A CD8 PE-Cy7-A
C
D
56
 P
E-
A
CD3+: 94% of
lymphocytes
CD3neg
C
D
45
 A
PC
-C
y7
-A
CD8+CD56+:
75% of CD3+
CD8+CD56neg
CD8neg
CD56neg
Sample Chr Posit Ref Var Depth Var. freq.Protein Freq.ratio
CD3+CD8+CD56+ 17 40359659 T A 18012 46% Y665F 1.01
CD3+CD8+CD56neg 17 40359659 T A 7329 4% Y665F 1.00
CD3+CD8negCD56neg No mutations
CD3neg 17 40359659 T A 529 2% Y665F 0.83
C
D
56
 P
E-
A
CD3+: 98% of
lymphocytes
CD3neg
C
D
45
 A
PC
-C
y7
-A
CD8+CD56+:
86% of CD3+
CD8+CD56neg
CD8neg
CD56neg
CD3 APC-A CD8 PE-Cy7-A
Sample Chr Posit Ref Var Depth Var. freq.Protein Freq.ratio
CD3+CD8+CD56+ 17 40359659 T A 15507 48% Y665F 1.02
CD3+CD8+CD56neg 17 40359659 T A 10217 2% Y665F 0.96
CD3+CD8+CD56neg 17 40359729 T G 10216 1% N642H 0.93
CD3+CD8negCD56neg 17 40359659 T A 7660 1% Y665F 0.89
CD3neg 17 40359659 T A 3022 18% Y665F 1.02
 54 
Patients 4 and 5 (Table 13) carried the STAT5B N642H mutation, and the 
mutation burden in different lymphocyte subpopulations was analyzed using amplicon 
sequencing. 
Patient 4 (Table 13) had a rare, aggressive CD56+ T-LGL leukemia. N642H was 
seen with extremely high VAF (92%) in the screening of PB MNC DNA. 
Concordantly, the proportion of CD3+CD56+ leukemic cells of lymphocytes was 
97% and the VAF of N642H mutation in leukemic CD3+CD56+ fraction was 99%, 
suggesting either a homozygous mutation or a loss-of-heterozygosity event (Figure 
17). Normal NK cells and B cells were too low in number for sorting. Small 
CD3+CD16/56negCD19neg T cell population harbored N642H with low frequency, but 
this could be related to the purity of the sorted fraction (Figure 17). 
 
 
Figure 17. Sorting and STAT5B amplicon sequencing results of patient 4 in study III 
(Table 13). 
 
Patient 5 (Table 13) had LGL leukemia with an aggressive clinical presentation. 
In addition to the leukemic CD3negCD16/56+ NK cell expansion, the patient also had 
an abnormal CD3+CD16/56+ T cell population, and both were mutated with high 
VAF (Figure 18). Due to the low number of cells, other lymphocyte fractions were 
not sequenced for STAT5B mutations.   
 
 
 
Figure 18. Sorting and STAT5B amplicon sequencing results of patient 5 in study III 
(Table 13). 
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To summarize the results of flow cytometry-assisted sorting and amplicon 
sequencing of STAT5B-mutated patients, all had leukemic LGL-populations of either 
T or NK lineage expressing the CD56 antigen. In the case of patients 2 and 3 (Table 
6), CD4+ fractions were unmutated but patient 3 also harbored STAT5B Y665F in NK 
cells (Figure 16). The last two patients (Table 13) had more aggressive disease, and 
the numbers of CD4+ or CD19+ cells were too low for sorting. In addition to the 
mutated leukemic population, patient 4 carried STAT5B N642H with low VAF in 
CD3+CD16/56neg cells (Figure 17), whereas the mutation was detected in both CD3neg 
and CD3+ cells of patient 5 with high VAF (Figure 18). 
 
16.5. Location of the LGL leukemia mutations in STAT3 and STAT5B protein 
structure (I, II, III, IV) 
In total, 16 different STAT3 mutations were detected in studies I, II, and IV. 
STAT3 mutations and their frequencies in patient cohorts are summarized in Table 14. 
The localization of mutations in the STAT3 protein structure is presented in Figures 
19 and 20.  
 
Table 14. Different STAT3 SH2 domain mutations in studies I, II, and IV. Mutations 
seen in patients with multiple mutations in study IV are marked with an “x.” 
Study Study I Study II Study IV 
Patients in the 
study 
T-LGL (n=77) T-LGL (n=120) CLPD-NK 
(n=50) 
T-LGL (n=174) CLPD-NK (n=39) 
1 
mutation 
≥2 
mutations 
1 mutation ≥2 
mutations 
S614R  3 (3%)      
G618R   1 (2%)     
Y640F 13 (17%) 14 (12%) 4 (8%) 32 X 1 X 
Q643H     X   
N647I 3 (4%) 1 (1%) 2 (4%) 2 X 2  
K658M  1 (1%)      
K658N 1 (1%)   1    
K658R     X   
I659L     X 1  
D661H 1 (1%)   1    
D661I   1 (2%)     
D661V 7 (9%) 3 (3%)  4 X   
D661Y 7 (9%) 12 (10%) 7 (14%) 16 X 2 X 
P678S     X   
Y657_K658insY 1 (1%)   1    
Y657_ins nonsense    1    
STAT3-mutated 
patients, total 
31/77 (43%)1 34/120 (28%) 15/50 (30%) 58 17 6 1 
75/174 (43%) 7/39 (18%) 
1Two patients in study I had two STAT3 mutations (Y640F+D661Y, D661V+N647I) 
 
 
 
 
 
Figure 19. STAT3 mutations of studies I, II, and IV are placed in linear presentation 
of STAT3 protein domains. Transcriptional activity-regulating, phosphorylating Y705 
and S727 residues are marked below.  
 
 56 
 
 
Figure 20. 3D model of the SH2 and DNA-binding domains of dimerized STAT3 
attached to target DNA. Mutated residues seen in studies I, II and IV are marked in 
one monomer. All recurrently mutated amino acids are localized in protein surface 
loops, facing the other STAT3 monomer. The structure is predicted in Becker et al. 
Nature 1998112, and RCSB Protein Data Bank code is 1BG1. 
 
The only STAT5B mutations seen in LGL leukemia so far are Y665F and N642H 
(2/211, 1% and 2/211, 1% in study III, respectively). Their localization in the 
STAT5B protein structure is shown in Figures 21 and 22. 
 
Figure 21. Linear model of STAT5B protein with mutations N642H and Y665F 
detected in study III. 
 
 
Figure 22. STAT5B mutations N642H and 
Y665F projected on a 3D model of STAT5A 
monomer protein structure, isolated from the 
unphosphorylated STAT5A trimer complex 
(RCSB Protein Data Bank 1Y1Y, published by 
Neculai et al. J Biol Chem 2005114). STAT5A 
and STAT5B share over 90% sequence 
homology. Similar to STAT3 mutations, 
N642H and Y665F are located on the surface 
loops of the SH2 domain (study III). 
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17. Functional studies with mutated STAT3 (I, II) 
17.1. Western blotting results of T-LGL leukemia patients with STAT3 mutation 
(I, II) 
STAT3 protein is tyrosine-phosphorylated in its active dimer form. The effects of 
STAT3 mutations on the tyrosine phosphorylation status were examined using western 
blotting with pSTAT3 and total-STAT3 antibodies. In addition to the PB MNC lysate, 
the analysis was performed from cytosolic and nuclear fractions to decipher the 
cellular localization of mutated STAT3 protein. The two patients with STAT3 
mutations D661V and Y640F expressed pSTAT3 in nuclear fractions (Figure 23).  
In study II, pSTAT3 levels were analyzed from PB MNC lysates, and patients 
with mutated and wild type STAT3 protein alike expressed pSTAT3 (data not 
shown). 
 
 
Figure 23. STAT3 western blotting results of a healthy control and two T-LGL 
leukemia patients with STAT3 mutations (study I). Patient 1 is presented in Table 6. 
Abbreviations: W, PB MNC whole cell-lysate; C, cytosolic fraction (of PB MNC); N, 
nuclear fraction (of PB MNC). 
 
 
17.2. Phospho-STAT3 immunohistochemistry from LGL leukemia patient bone 
marrow samples (I) 
BM biopsies stained with anti-pSTAT3Y705 and anti-CD57 antibodies were 
examined from 3 STAT3-mutated patients and 1 healthy control in study I. All LGL 
leukemia patients displayed positive nuclear staining of BM-infiltrating lymphocytes 
with pSTAT3Y705 antibody, and the lymphocytes were also CD57+ (Figure 24).  
Similar anti-pSTAT3 staining was performed using slides obtained from two 
STAT3 mutation-negative patients, both of whom demonstrated nuclear localization of 
pSTAT3Y705, although to a lesser extent compared to the STAT3-mutated patients 
(Figure 25). 
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Figure 24. IHC results from two STAT3-mutated T-LGL leukemia patients and a 
healthy control (study I). Anti-pSTAT3Y705 (upper panel) and anti-CD57 (lower 
panel) are marked with brown staining (magnification x63) 
 
 
 
 
Figure 25. Anti-pSTAT3Y705 IHC results from two T-LGL leukemia patients (A and B 
present two different patients) with wild type STAT3 (magnification x63) 
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17.3. Transcriptional activity of mutated STAT3 using reporter assay (I) 
STAT3 is a transcription factor, and one way to measure the effects of SH2 
domain mutations is to analyze the transcriptional activity of mutated versus wild type 
STAT3. HEK2 cells were simultaneously transfected with constructs containing 
either wild type or Y640F/D661V mutated STAT3, and a luciferase construct driven 
by STAT3-responsive SIE. Luciferase activity was measured in triplicates after mock 
or IL-6 stimulation. Both mutated constructs, especially Y640F, showed increased 
transcriptional activity at baseline and after IL-6 stimulation (Figure 26). 
 
 
Figure 26. STAT3 reporter assay results. 
Analysis was done in triplicates (study I). 
Columns present mean intensities and I bars 
mark range. 
 
 
 
 
 
18. Functional studies with mutated STAT5B (III) 
18.1. Western blotting results of T-LGL leukemia patients with STAT5B 
mutation (III) 
Similar to STAT3, activation of STAT5B is also tyrosine phosphorylation-
dependent. The tyrosine phosphorylation levels of mutated STAT5B were analyzed 
with Western blotting, using antibodies for pSTAT5Y694, total STAT5, pSTAT3Y705 
and total STAT3. The analysis was done from PB MNC nuclear lysates of STAT5B 
Y665F-mutated T-LGL leukemia patients (n=2), STAT3/STAT5B-unmutated T-LGL 
leukemia patients (n=3) and healthy controls (n=5) (Figure 27). The STAT5B-
mutated patients expressed pSTAT5 in nuclear fraction, but it was not seen in other 
samples (Figure 27). GAPDH was used as a control of protein load, but no nuclear-
specific control was included in the assay.  
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Figure 27. Western blotting results from PB MNC nuclear lysates of T-LGL leukemia 
patients and healthy controls (study III). 
 
18.2. Analysis of STAT5 phosphorylation using enzyme-linked immunosorbent 
assay (III) 
Phosphorylated and total STAT5 protein was analyzed with enzyme-linked 
immunosorbent assay (ELISA) in addition to Western blotting in study III. Protein 
lysates from PB MNC fraction were used in the analysis. The pSTAT5 antibodies 
detect pSTAT5AY699 and pSTAT5BY964. The two T-LGL leukemia patients with 
STAT5B Y665F mutation showed increased amount of pSTAT5 when compared to 
STAT3-mutated  (n=2) or STAT3/STAT5B wild type (n=4) LGL leukemia patients 
and healthy controls (n=4) (Figure 28). Thus, the results were in accordance with the 
pSTAT5 western blotting analysis. 
 
 
 
Figure 28. Results of pSTAT5 and STAT5 ELISA (study III). Horizontal lines define 
median intensities. 
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18.3. Transcriptional activity of mutated STAT5B using reporter assay (III) 
The transcriptional activity of the STAT5B proteins was analyzed in HeLa cells. 
A wild-type STAT5B construct, or a construct containing either the N642H or Y665F 
mutation, were transfected into HeLa cells together with a luciferase reporter gene 
under the control of STAT5 response element. Both mutated vectors, especially 
N642H, activated the transcription of luciferase without cytokine stimulation (Figure 
29).  
 
Figure 29. Results of STAT5B reporter assay with 
wild-type, Y665F and N642H constructs (study III). 
Analysis was done in triplicate. Columns present 
means intensities and I bars mark range. 
 
 
 
 
 
19. Gene expression analysis in LGL leukemia patients (I, II, III) 
Gene expression analysis was performed in studies I (RNA sequencing and 
microarray), II (microarray), and III (RNA sequencing and microarray). RNA 
sequencing data in study III was used only to analyze the expression of genes with 
somatic mutations. 
In study I, the gene expression in CD8+ cells of STAT3-mutated (n=8) and 
unmutated (n=10) T-LGL leukemia patients and healthy controls (n=5) were 
compared using an Illumina Human HT-12v4 microarray. The expression levels of 
selected STAT3-responsive genes and other JAK-STAT-related genes are shown in 
Figure 30. The expression of IL-6, an upstream regulator of STAT3, showed a wide 
variation within the group of STAT3-mutated patients (Figure 30). The expression of 
JAK2, which is both STAT3 upstream regulator and STAT3 target gene126, did not 
differ significantly between mutated and unmutated patients, although its expression 
was higher in STAT3-mutated patients versus healthy controls (Figure 30). SOCS3 
expression levels were similar in all groups (Figure 30). In the comparison of the 
RNA sequencing data of CD8+ T cells from T-LGL leukemia index patient (carrying 
the D661V mutation) and healthy control CD8+ T cell RNA several STAT3-
responsive genes were upregulated, including FASL and JAK2 (data not shown).126 
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Figure 30. Expression array results of selected STAT3 responsive genes and other 
JAK-STAT related genes of study I. Mean relative intensity is shown (logarithmic 
scale) and I bars present standard error of mean. Statistical significance of 
differences between expression levels are marked as follows: *, p<0.05; **, p<0.01; 
***, p<0.001; ns, not significant. 
 
The gene expression comparison using Affymetrix microarray in study II 
consisted of both STAT3-mutated (n=2) and unmutated (n=1) T-LGL leukemia 
patients and healthy controls (n=3). T-LGL expansions from LGL leukemia patients 
were sorted based on the Vbeta expression on CD8+ cells, and CD8+CD57+ T cells 
from healthy individuals were used as controls. Similar to study I, several STAT3-
downstream genes125 were upregulated in both STAT3-mutated and –unmutated 
patients (data not shown). 
 
In study III, novel STAT5B mutations added a new group to the gene expression 
analysis: CD8+ RNA was extracted from STAT5B Y665F mutated (n=2) and N642H 
mutated (n=1) patients, 3 patients harboring a STAT3 mutation, and 2 patients with 
wild type STAT3 and STAT5B (confirmed by exome sequencing, results are not 
presented in this thesis). CD8+ (n=2) and NK cells (n=2) were separated from healthy 
individuals (anonymous Finnish Red Cross buffy coat samples) and were used both as 
controls and biological replicates in the assay. LGL leukemia patients carrying the 
STAT5B Y665F mutation grouped together in the clustering analysis, and belonged to 
the same branch of the dendrogram with other LGL leukemia patients (Figure 31). 
Healthy controls were one group, and patient 5 with the STAT5B N642H mutation 
(Table 13) was an outlier as was expected based on the aggressive clinical 
presentation (Figure 31). Related to the data of the distance dendrogram, the gene 
expression profiles of LGL leukemia patients were very similar, independent of the 
mutation status, and no significantly differentially expressed genes were found in a 
comparison of STAT3+ vs. STAT5B+ vs. wild-type STAT3/STAT5B LGL leukemia 
patients. The analysis of STAT5B mutated patients versus healthy CD8+ controls 
yielded 4894 genes with diverging expression (p<0.05). In subsequent comparison, 
the expression levels of the most over- and underexpressed of these genes were 
remarkably similar between all LGL leukemia patients (patient 5, Table 13, was 
excluded from the analysis) (Figure 32). 
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Figure 31. Distance dendrogram of the gene expression profiles between LGL 
leukemia patients and healthy controls (study III). Each balloon represents one LGL 
leukemia patient or one healthy control. The type of the STAT3 mutation is marked 
under the balloon. 
 
 
 
Figure 32. Gene expression levels of selected differentially expressed genes in LGL 
leukemia patients and healthy controls in study III (log2 scale).  
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20. Clonal hierarchy in LGL leukemia (IV) 
In study I, the STAT3 D661V mutation of patient 1 (Table 6) was located only in 
the CD8+Vb16+ immunodominant clone and other lymphocyte subpopulations were 
unmutated (Figure 10), whereas in the case of STAT5B mutated patients, the 
mutations were also harbored by other lymphocyte fractions in addition to the 
mutated major clone (Figures 15-18). In study IV, amplicon sequencing revealed that 
a substantial proportion of the LGL leukemia patients carried multiple STAT3 
mutations, existing either in the same or different clones (Figure 14, Table 14). 
Consequently, the exact location of STAT3 mutations and clonal hierarchy of 
lymphocytes was analyzed in study IV using flow cytometry-assisted sorting and 
amplicon sequencing of the STAT3 exon 21. Samples were available from 12 T-LGL 
leukemia and 1 CLPD-NK patients. Healthy control BM samples (n=10) and reactive 
LGL expansions of dasatinib-treated CML patients (n=8) were also analyzed, but they 
all had wild type exon 21 of STAT3. 
 
20.1. STAT3 mutations in lymphocyte subpopulations (IV) 
In the case of T-LGL leukemia patients, Vbeta analysis data were the basis of the 
sorting of different lymphocyte fractions. CD8+ lymphocyte fraction was divided into 
Vbeta-positive (LGL expansion) and –negative cells, and in addition CD4+ 
lymphocytes, CD3negCDCD16/56+ NK cells and CD3negCD19+ B cells were sorted 
and analyzed. 
Samples from T-LGL leukemia patients with one major immunodominant 
expansion in Vbeta analysis and only one STAT3 mutation in the original screening 
revealed that in 4 of 5 cases analyzed, the STAT3 Y640F mutation was located solely 
in the immunodominant expansion (Figure 33). In one patient, three additional 
STAT3 mutations with low VAF were detected in the seemingly polyclonal 
CD8+Vb21.3neg fraction (Figure 33C). In all five cases, CD4+, NK, and B cells were 
unmutated.  
 
 
 
Figure 33. Three examples of Vbeta results (proportion of LGL expansion/CD8+ 
cells) and the location and VAF of STAT3 mutations in sorted fractions in study IV. 
Patients in A and B had monoclonal STAT3-mutated expansion, whereas the patient 
shown in C had three minor STAT3-mutated clones in the Vb21.3neg fraction in 
addition to the mutated Vb21.3+ clone. 
Axes: A: Vb13.1-PE, Vb8-FITC, Vb13.6-PE+FITC. B: Vb5.3-PE, Vb3-FITC, Vb7.1-PE+FITC. C: 
Vb23-PE, Vb21.3-FITC, Vb1-PE+FITC. 
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Two patients with multiple STAT3 mutations in the original screening were 
similarly sorted and analyzed. As an extreme example, the first of these patients had a 
total number of four different STAT3 mutations, two of which were situated in 
separate Vb-positive expansions and the other two in polyclonal CD8+ fraction 
(Figure 34A-B). The second patient harbored two STAT3 mutations in two CD8+ 
expansions (Figure 34C-D). Other lymphocyte populations did not carry STAT3 
mutations. 
 
 
 
 
Figure 34. Vbeta results (proportion of LGL expansion/CD8+ cells) and the location 
and VAF of STAT3 mutations in sorted fractions in study IV. The first patient had four 
different STAT3 mutations (A-B), whereas the second patient harbored only two 
STAT3 mutations in two separate Vbeta expansions (C-D). The percentage of Vbeta 
expansion is shown, and the numbers after mutations stand for VAF. 
Axes:A: Vb5.3-PE, Vb3-FITC, Vb7.1-PE+FITC. B: Vb18-PE, Vb20-FITC, Vb5.1-PE+FITC. C: Vb9-
PE, Vb16-FITC, Vb17-PE+FITC. D: Vb13.1-PE, Vb8-FITC, Vb13.6-PE+FITC. 
 
20.2. TCRB sequencing of STAT3 mutated T-LGL leukemia patients (IV) 
Second generation sequencing enables the analysis of TCRB CDR3 
rearrangement repertoires at a new level, compared to capillary sequencing where 
only major clones can be detected and sequenced, or flow cytometry analysis, which 
does not recognize all TCRB rearrangements and does not give data on the CDR3 
amino acid sequence. In many flow cytometry-sorted cases, STAT3 mutations were 
located in apparently polyclonal parts of the CD8+ lymphocyte population. The exact 
amino acid sequence of the TCRB CDR3 region could also clarify the quality (nature) 
of antigens behind leukemic expansions. Thus, three T-LGL patients with multiple 
STAT3 mutations were chosen for detailed analysis of the TCRB CDR3 repertoire. 
The patients were not HLA-matched. The results of two patients are presented here as 
an example. 
 
The first patient harbored two STAT3 mutations: Y640F in the immunodominant 
Vb3+ expansion and I659L in Vb3neg CD8+ cells (Figure 35A). The patient was 
anemic and was treated with MTX: both clones persisted during and after MTX 
treatment (Figure 35B). In the TCRB CDR3 analysis, the Vb3+ population consisted 
mostly of a major rearrangement (74%), and the Vb3neg fraction was similarly skewed 
with a single rearrangement of 74% of the reads (Figure 35C-D). Simpson’s diversity 
indexes for Vb3+ and Vb3neg fractions were 0.45 and 0.45, respectively, emphasizing 
the level of narrowing of the TCRB CDR3 repertoire in the CD8+ lymphocytes. 
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Figure 35. Vbeta analysis (A), STAT3 amplicon sequencing results (A) and 
laboratory values (C) of a T-LGL leukemia patient with two STAT3 mutations in study 
IV. TCRB CDR3 deep sequencing was done after 33 months follow-up: the results of 
sorted Vb3+ expansion (C) and Vb3neg cells (D) are shown, with CDR3 amino acid 
sequences of the largest rearrangements indicated.  
 
The STAT3 mutation status of the second patient is presented in Figure 33C: in 
addition to the N647I-mutated Vb21.3+ immunodominant clone, the patient carried 
three STAT3 mutations in Vb21.3neg cells. The Vb21.3+ fraction harbored a major 
TCRB rearrangement of 63%, and surprisingly also another rearrangement with an 
unresolved V-gene (26%) (Figure 36A). The sorted Vb21.3+ population looked 
almost 100% pure in flow cytometry analysis, indicating that both expansions were 
recognized by the same Vbeta mAb despite the different CDR3 amino acid sequence. 
The VAF of STAT3 N647I was 33%, corresponding well to the percentage of the 
major CDR3 rearrangement, whereas the smaller expansion was probably unmutated 
(Figure 36). The Vb21.3neg cells contained only three small expansions of 4%, 3%, 
and 2%, which could represent small STAT3 mutated clones seen in amplicon 
sequencing (Figure 36B). Simpson’s diversity index for the Vb21.3+ fraction was 
0.53, related to the narrowing of the TCRB repertoire. The Vb21.3neg sample did not 
contain large expansions, and the diversity index was 0.97, suggesting a relatively 
normal TCRB CDR3 repertoire. 
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Figure 36. TCRB sequencing results and CDR3 amino acid sequences of a T-LGL 
leukemia patient with four STAT3 mutations, all in different clones in study IV (shown 
in Figure 33C). Sorted Vb21.3+ fraction consisted mostly of two different TCRB 
rearrangements (A), both recognized by the same Vbeta mAb although the amino acid 
sequences were dissimilar. The Vb21.3neg fraction appeared more polyclonal and the 
four largest rearrangements are marked (B). 
 
The 20 most frequent TCRB CDR3 amino acid sequences of each patient were 
compared to the TCRB CDR3 repertoire of other patients, but all sequences were 
private and did not exist in the other T-LGL leukemia patients analyzed. No similarity 
was seen between amino acid sequences of multiple rearrangements within one 
patient. However, the CDR3 rearrangements of the immunodominant clone in two 
patients were seen with low frequency in healthy controls (only 100% matches taken 
into consideration, data not shown). The patient presented in Figure 35 had the most 
skewed TCRB repertoire, and in the comparison of the five largest rearrangements, 
none were shared with healthy individuals (n=165). 
 
20.3. STAT3 mutations during follow-up and treatment of LGL leukemia 
patients (IV) 
Sorted samples from different timepoints were analyzed from STAT3-mutated 
LGL leukemia patients treated with MTX (n=2) and cyclophosphamide (n=3). The 
median observation period was 33 months.  
Both patients treated with MTX had T-LGL leukemia. The results of a patient 
with STAT3 mutations Y640F and I659L are presented in Figure 35A-B: the size of 
Vb3+ Y640F-mutated clone was unchanged during therapy, whereas the proportion of 
I659L-mutated cells in Vb3neg fraction was slightly lower during MTX therapy. The 
patient achieved partial response as hemoglobin values improved during treatment 
(Figure 35B). The treatment response of the second patient was similar, with 
improvement in hemoglobin levels, but the Y640F-mutated Vb17+ clone was 
unchanged (Figure 37).  
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Figure 37. Results of flow cytometry and STAT3 amplicon sequencing of a T-LGL 
leukemia patient (A), and laboratory values of the same patient during follow-up (B) 
in study IV. 
 
Among the patients (n=3) treated with cyclophosphamide, 2 patients showed 
better treatment responses compared to MTX-treated patients. The first patient was 
diagnosed with T-LGL leukemia, but the major CD8+Vb20+ clone was unmutated, 
whereas an aberrant CD3negCD16/56neg fraction harbored a D661Y mutation (Figure 
38A). The patient went to complete remission, during which both the Vb20+ clone 
and D661Y-mutated cells were suppressed and normal NK cell population was 
restored (Figure 38A-B). The second patient was diagnosed with CLPD-NK, but 
similarly to the first patient, D661I-mutated cells had the abnormal phenotype of 
CD3negCD16/56neg. The mutated cells were eradicated during cyclophosphamide 
therapy, with the rise of a normal NK cell fraction (Figure 38C-D). After cessation of 
cyclophosphamide administration, the mutated cells returned, but no follow-up data 
from later timepoints exist (Figure 38C). 
 
 
 
Figure 38. Results of flow cytometry analysis, STAT3 amplicon sequencing, and 
blood counts at different timepoints from two cyclophosphamide-treated patients in 
study IV. (A-B) The first patient was diagnosed with T-LGL leukemia, but a D661Y-
mutation was in CD3 neg cells; this disappeared during complete remission. (C-D) The 
second patient had CLPD-NK and complete remission was connected to the 
eradication of mutated cells and recovery from anemia.  
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The third cyclophosphamide-treated T-LGL leukemia patient had two STAT3 
mutations in two separate clones (Figure 39). The patient failed therapy, after which 
only the major Vb13.6+ clone with the D661Y mutation was seen in amplicon 
sequencing analysis, whereas the minor clone harboring the D661V mutation 
disappeared (Figure 39). 
 
  
Figure 39. Results of a T-LGL leukemia patient who failed cyclophosphamide therapy 
(study IV). The minor D661V-mutated clone disappeared, while cyclophosphamide 
did not have any effect on the major Vb13.6+ clone (A). (B) Laboratory values at 
different time points.  
 
 
21. Clinical impact of STAT3 and STATB mutations in LGL leukemia 
(I, II, III, IV) 
The clinical impact of STAT3 mutations was assessed in studies I, II and IV.  
In study I, the comparison was made between STAT3 mutated and unmutated T-
LGL leukemia patients and also between the three most common mutations (Y640F, 
D661Y, and D661V). STAT3 mutation-carrying patients were more often neutropenic 
(24/31, 77% vs. 23/46, 50%, p=0.02) and had concomitant RA (26% vs. 6%, p=0.02). 
The patients chosen for study I had all monoclonal T-LGL leukemia: a slight 
difference was seen in the size of the major clone between mutated and unmutated 
cases (median clone sizes 89% [range 62-99%] and 77% [range 34-96%], p=0.03). No 
significant differences were observed between carriers of different STAT3 mutations, 
but this could be due to the low number of patients in each group. 
The analysis in study II was concordant with study I: RA was more frequent in 
STAT3-mutated cases (18% vs. 7%, p=0.024) and autoimmune hemolytic anemia was 
also more common in mutated patients (14% vs. 4%, p=0.039). The size of the 
immunodominant clone was over 25% of the CD8+ cells in all cases harboring STAT3 
mutations, whereas among nonmutated cases, 23% of the patients had clones smaller 
than 25%. The pattern of KIR expression was analyzed from 25 CLPD-NK patients, 7 
of which carried STAT3 mutations: almost all analyzed patients (23/25) had abnormal 
KIR expression, including all mutated cases. STAT3-mutated patients needed more 
lines of therapy during the observation period (median number of therapies 2.4 vs. 
1.2, p=0.03). The presence of mutations or the type of LGL leukemia (T-LGL or 
CLPD-NK) did not affect overall survival. 
A large proportion of patients in the study IV cohort harbored multiple mutations 
in the STAT3 gene. Thus, T-LGL leukemia patients were divided into three groups: 
unmutated patients (n=99), patients with one STAT3 mutation (n=58), and patients 
harboring ≥2 mutations (n=17). Only 1 of 7 STAT3-mutated CLPD-NK patients had 
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≥2 mutations, and the comparison of CLPD-NK patients revealed no statistically 
significant differences between mutated or nonmutated patients. The most interesting 
difference in the T-LGL leukemia cohort was the prevalence of RA: it was seen in 
41% of patients with ≥2 mutations vs. 22% of patients with one mutation vs. 6% of 
unmutated patients (p=0.0001). The median size of the immunodominant clone was 
the highest in patients with one mutation (83%), whereas in patients with multiple 
mutations it was 65%, probably related to the existence of multiple clones 
(p<0.0001). Neutrophil count at diagnosis was the lowest in patients with multiple 
mutations, but did not reach statistical significance. The T-LGL leukemia patients 
carrying Y640F (n=33) or D661Y (n=18) mutation were also compared: patients 
harboring D661Y had lower hemoglobin values than Y640F-mutated patients, but 
higher leukocyte and lymphocyte counts (median hemoglobin 104 vs. 122 g/l, 
p=0.0449, leukocytes 12.4 vs. 5.1 x106/l, p=0.0440, lymphocytes 7.5 vs. 3.2 x106/l, 
p=0.0028, respectively). 
 
The number of patients harboring STAT5B mutations in study III was low (4/211, 
2%) and the calculation of statistics was not possible. However, some notions were 
made based on the mutation status and clinical information. Leukemic LGLs of all 
STAT5B-mutated patients expressed CD56 antigen on their surface, one case being 
classified as CD3neg NK-cell type LGL leukemia (with concomitant aberrant 
CD3+CD56+ population) whereas 3 cases were rare CD8+CD56+ T-LGL leukemias 
(Tables 6 and 13). The two patients (Table 13) carrying a STAT5B N642H mutation 
were the only cases in the cohort of 211 patients with untypical, aggressive LGL-
leukemia, suggesting a correlation between STAT5B N642H and an aggressive 
clinical picture. 
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DISCUSSION 
Since the discovery and characterization of LGL leukemia nearly thirty years ago, 
researchers have speculated whether the disease is caused by dysregulated T cell 
homeostasis resulting in extremely prolonged immune response, or by malignant 
transformation leading to chronic lymphoproliferative disease.1,2 Considering the 
former hypothesis, several studies have shown that multiple cell survival and 
apoptosis-related signaling pathways function aberrantly in LGL leukemia, but the 
actual antigen causing the initial immune activation has not been discovered. Despite 
the detailed mapping of several molecular abnormalities in leukemic LGLs, these 
discoveries have not yet led to the development of targeted therapies.100 The latter 
theory of oncogenic transformation behind LGL leukemia contains an idea of possible 
somatic mutations, which lead to the expansion of LGL clone. In many malignancies, 
emerging second-generation sequencing and bioinformatics tools have deepened the 
understanding of molecular events causing transformation and consequently led to the 
discovery of novel targeted therapies.  
 
The goal of the first study was to explore the genetic landscape in LGL leukemia 
using second-generation sequencing methods. The application of exome sequencing 
proved to be successful and led to the major discovery of the thesis: 40% of T-LGL 
leukemia patients harbored somatic mutations in the STAT3 gene, and in study II, 
similar STAT3 mutations were seen also in 30% of CLPD-NK patients. The original 
results of STAT3 mutations in study I have been reproducible: the frequency rate of 
mutations is up to 70% in T-LGL leukemia and 30-40% in CLPD-NK in different 
publications.210,211 Sporadic STAT3-mutated cases have been reported among diffuse 
large B cell lymphoma (DLBCL) and T cell lymphoma (especially in anaplastic 
CD30+ T cell lymphoma) patients, but in solid tumors, they are practically absent.211-
214 
  
The inspection of the STAT3 protein 3D model suggested that these mutations 
could change the dimerization properties of STAT3. All recurrent mutations were 
located in the specific surface loops of STAT3 SH2 domain. Mutated residues Y657, 
K658, I659, and D661 belong to the BG loop (amino acids 656-677) near the C-
terminal, and interestingly, substitution of A662 and N664 of BG loop with cysteine 
results in sulfhydryl bonds between STAT3 monomers and creates a constitutively 
active STAT3 dimer (STAT3-C).113 Frequently mutated amino acid Y640 is located 
in another surface loop annotated as DB, and S614 and G618 seen in study II are 
situated in a third loop (βC) next to DB.112 All these loops are in close contact with 
the other STAT3 monomer during dimerization of STAT3, and the BG loop is 
situated next to the phosphotyrosine-binding pocket.112  Notably, the mutations seen 
in LGL leukemia are different from the germline mutations of hyper-IgE syndrome 
patients, which are thought to function in a dominant-negative manner.139,140 STAT3 
SH2 domain mutations caused constitutive phosphorylation of STAT3 and increased 
its transcriptional activity in the experiments of study I and II. Some DLBCL 
mutations were located in the coiled-coil domain of STAT3 near nuclear import 
sequence, and functional data of one of these (M206K) showed increased 
phosphorylation and transcriptional potential, consistent with the effects of SH2 
domain mutations.213 The most common mutation, Y640F, was able to cause 
leukemic transformation in a mouse bone marrow model.212 Taken together, structural 
data and results of functional experiments led to the hypothesis that STAT3 SH2 
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domain mutations could stabilize the reciprocal phosphotyrosine-SH2 interaction and 
strengthen the dimer structure of STAT3. STAT3-C is activated independent of 
phosphorylation status, but it has not been confirmed whether the mutations of LGL 
leukemia patients require phosphorylation of Y705 in order to convey their effects. 
 
Study III focused on the analysis of somatic mutations in STAT3 mutation-
negative LGL leukemia patients by means of exome sequencing. This resulted in a 
new candidate gene, as two T-LGL leukemia patients harbored a novel gain-of-
function STAT5B mutation Y665F in the leukemic CD8+ clone. In the following deep 
sequencing-based screening of STAT5B exon 16, two additional patients carried 
another activating STAT5B mutation N642H. Residues N642 and Y665 are situated 
on the surface of the SH2 domain, but their location in relation to the other STAT5B 
monomer in the dimerized and phosphorylated structure cannot be assessed in detail, 
as a molecular model does not exist. The four LGL leukemia patients (one NK cell, 
three T-LGL) with STAT5B mutations expressed CD56, which is a typical NK cell 
antigen. CD56-expressing CD8+ T cells possess more robust cytotoxic activity, which 
can also be MHC-unrestricted, similar to NK cells.215 Mutated STAT5B could cause 
transcription of genes that program cells to an NK-like CD56+ phenotype. The two 
patients carrying a STAT5B N642H mutation were the only cases with untypical and 
fatal LGL-leukemia, indicating a connection between the mutation and aggressive 
phenotype. This is supported by the recent discovery of similar STAT5B mutations in 
T-ALL: in a cohort of 64 adult T-ALL patients, 7/64 (11%) carried activating 
STAT5B mutations (the N642H was harbored by 6 cases).216 
 
STAT3 and STAT5B share interesting structural and functional properties: both 
are pleiotropic transcription factors with a crucial role in lymphocyte biology.116 
Furthermore, although their upstream activators are different and their target genes 
depend on the cell type, ChIP-seq based analysis of T lymphocytes showed that over 
90% of the STAT5 target sequences are co-occupied with STAT3.156 However, in 
some cases their action seems to reciprocal, such as in the case of Th17 differentiation 
through binding of STAT3 or STAT5B to Il17 gene locus.165 The combined 
prevalence of STAT3 and STAT5B mutations does not cover all LGL leukemia cases. 
The gene expression profiles of LGL leukemia patients in the microarray analysis of 
studies I, II, and III resembled each other, independent of STAT3/STAT5B mutation 
status, indicating that in patients with the wild type STAT3/STAT5B, JAK-STAT axis 
could be activated by alternative means. Furthermore, previous studies have shown 
that STAT3 is universally activated in LGL leukemia.4 Two recent studies using 
exome sequencing have suggested potential candidate genes both upstream and 
downstream of STAT3: in the first paper, one of the mutations was located in a 
conserved miRNA binding site of IL6R and it could potentially alter translation of 
IL6R gene.217 Mutations in a related gene, IL6ST, have been described in 
inflammatory hepatocellular adenoma, where STAT3 mutations are also seen with low 
frequency.218,219 In another study, the most interesting finding was a missense 
mutation in PTPRT, which dephosphorylates STAT3: a defect in dephosphorylation 
of Y705 could lead to constitutive activation of STAT3.220 However, all the variants 
in these publications were seen in individual LGL leukemia patients and only STAT3 
and STA5B mutations have been recurrent thus far. 
 
The diagnosis of T-LGL leukemia requires confirmation of clonal rearrangement 
of TCR, but the number of clones and their size varies: some patients have 
 73 
monoclonal LGL leukemia, while others harbor smaller subclones in addition to the 
major expansion.72 The clonal pattern can even change during follow-up, a 
phenomenon designated as clonal drift.72 The data for multiple clones are in 
concordance with the results of study IV, in which 20% of STAT3 mutated patients 
harbored multiple STAT3 mutations, in most cases existing in different clones when 
analyzed by deep sequencing. The mutations were specific for CD8+ and NK cells, 
whereas CD4+ and CD19+ lymphocytes were unmutated in all samples. LGL 
leukemia patients do not commonly share immunodominant TCRB CDR3 sequences 
with each other, although in some cases the major clonotypes are seen in other 
patients.71,221 If multiple STAT3 mutated clones of one patient shared a similar TCRB 
CDR3 rearrangement, the expansions could have originally developed in response to 
the same antigen. Consequently, in study IV, the repertoire of the TCRB CDR3 
region was analyzed using a deep sequencing method, but the clones sorted and 
sequenced did not share common CDR3 rearrangements with other clonal expansions 
within the same or different patients. Although the results did not suggest a common 
antigen behind clonal expansion, the possibility of one was not excluded. 
 
One intriguing feature of T-LGL leukemia is the high incidence of concomitant 
autoimmune syndromes. The initial expansion and self-reactivity of cytotoxic LGLs 
could be related to crossreactivity between self-antigens and infectious agents. 
Several mechanisms causing activation of autoreactive lymphocytes have been 
described: in addition to crossreactivity (molecular mimicry), a tissue-destroying 
inflammatory reaction can lead to enhanced presentation of autoantigens by antigen-
presenting cells, followed by activation of autoreactive lymphocytes.222 Inflammation 
can arouse widespread immune activation, during which self-reactive lymphocyte 
clones also expand.222 The connection between lymphoid malignancies and certain 
lymphotropic viruses has been established. As an example, rare aggressive NK-LGL 
leukemia is often associated with EBV.223 HTLV-1 and -2 are retroviruses that have 
been connected with chemorefractory T cell lymphomas and autoimmunity.224 
Interestingly, autocrine IL-2 signaling is often reversed in HTLV-infected 
transformed cells, and IL-2-independent malignant lymphocytes start to express both 
STAT3 and STAT5 constitutively.224 No reports of possible activating JAK/STAT 
axis mutations in these cells exist. HTLV antibodies have been detected in the sera of 
LGL leukemia patients with a prevalence of 44% (23/53), but only a few patients 
were actually infected with HTLV-1/2, suggesting that positive titer results from 
contact with an HTLV-resembling epitope in most cases.75  
 
Normal control mechanisms of immunologic tolerance malfunction in LGL 
leukemia. The rearrangement of TCR determines the antigen target of a lymphocyte, 
and the positive selection of central tolerance allows only CD4+CD8+ thymocytes 
expressing TCR (which can interact with self-peptide-MHC complexes with moderate 
affinity) to differentiate into CD4+ or CD8+ lymphocytes. Central tolerance cannot 
eliminate all autoreactive lymphocytes, and two important mechanisms, anergy and 
activation-induced cell death (AICD), regulate autoreactivity in the periphery together 
with Tregs. Anergy is related to T cell surface receptors, which convey inhibitory 
signals and these include, for example, Cytotoxic T lymphocyte antigen 4 (CTLA-4) 
and Programmed cell death-1 (PD-1).225 No definitive data of the role of these 
proteins in LGL leukemia pathogenesis exist, although one study reported that T-LGL 
leukemic cells were CTLA-4-negative.226 AICD, on the other hand, has a pronounced 
role in LGL leukemia pathogenesis: leukemic LGLs are resistant to FAS-FASL-
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signaling, which is one of the main AICD-triggering pathways.85 Another T cell 
apoptosis-related pathway is mediated by the BCL-2 family proteins: in a previous 
publication describing STAT3 activation in LGL leukemia, the JAK2 inhibitor AG-
490 had no effect on BCL-2 expression, but reduced MCL-1 levels were observed 
together with STAT3-inhibition and restored FAS-sensitivity.4 Thus, mutated STAT3 
could possibly cause FAS-resistance and expansion of autoreactive cells, which are 
able to escape AICD. 
 
This idea is supported by the fact that STAT3 mutations have recently been 
observed in different autoreactive conditions. RA is the most common autoimmune 
disorder in LGL leukemia patients.7,12,24 In studies I, II and IV, the prevalence of RA 
was highest in STAT3-mutated patients, especially in those patients with multiple 
mutations. Felty’s syndrome is typically a late complication of RA, and STAT3 
mutations have been reported in patients with Felty’s syndrome and LGL expansion, 
suggesting that Felty’s syndrome and LGL leukemia with RA are truly overlapping 
conditions.227,228 LGL leukemia can also appear in the context of certain bone marrow 
defects such as PRCA, aplastic anemia (AA), and MDS, and it has been suspected 
that hematopoietic precursors could be the target of clonal self-reactive LGLs.229-231 
STAT3 mutations are relatively common in these syndromes, and they were detected 
in AA and MDS patients both with and without LGL leukemia. In patients with 
detectable LGL expansion, the frequency rates were 55% and 38% for AA and MDS, 
respectively, and the mutations were located in T cells when sorted bone marrow 
samples were analyzed. In patients without apparent LGL clones, the mutations were 
also seen in 7% (AA) and 3% (MDS) of the cases.232 In an Asian LGL leukemia 
cohort, the prevalence of STAT3 mutations was higher in LGL leukemia patients with 
concomitant PRCA (71% vs 5%), and STAT3-mutated patients more often had 
neutropenia and had lower treatment-free survival.233 
 
Why do STAT3, or STAT5B, mutations occur with such a high rate in LGL 
leukemia? One possible reason is the amplification and overexpression of the IL-6-
STAT3 axis caused by chronic immune activation.149,234 This could result in an 
increased number of somatic mutations in this specific pathway, because transcription 
of a gene correlates positively with the rate of mutagenesis.235 A hypothesis stating 
that LGL leukemia initiates from polyclonal immune activation and that mutations 
occur secondarily to activated lymphocytes is further supported by the fact that a 
marked proportion of study IV patients harbored multiple STAT3 mutations, existing 
in multiple clones in most cases analyzed. Considering mutations in STAT5B, IL-15 
and PDGF were able to sustain a leukemic population in a network model of LGL 
survival signaling.91 These both were connected to STAT3 activation in the same 
model, but they are also upstream regulators of STAT5B.91 IL-15 possesses 
interesting leukemogenic effects: If LGLs are cultured with IL-15 and then 
transplanted into mice, the mice develop malignant lymphoproliferation possibly due 
to genomic instability caused by prolonged IL-15 exposure. A similar mechanism 
could be related to the development of STAT5B mutations: IL-15 secretion is 
increased during different virus infections and autoimmune disorders, and it enhances 
NK cell function and stimulates the proliferation of memory T cells.236,237   
 
It is likely that STAT3-mutated clones accumulate during the course of LGL 
leukemia: the clonal landscape of LGL leukemia is often dynamic, and even major 
immunodominant clones can disappear with simultaneous appearance of other 
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expansions.72 A simplified model of clonal evolution in acute leukemias suggests that 
a sequential acquisition of mutations results in the development and dominance of 
certain subclones, but in reality this process is more complex and branched. In LGL 
leukemia, the clonal hierarchy is probably different, and in the case of multiple clones 
with or without STAT3 mutation, they could arise from originally polyclonal immune 
response to an antigen. Some LGL leukemia patients even harbor both NK and T cell 
expansions, which was the case in one patient analyzed in study IV.14 
 
The driving force of dynamic expansions could arise from the genetic 
background. Transcriptional activity of all different STAT3 mutations has not been 
analyzed, but possibly their potential to activate STAT3 is not similar. In most cases 
analyzed with STAT3 deep sequencing of sorted lymphocyte fractions, the patients 
with multiple mutations had one major STAT3-mutated clone and additional smaller 
mutated expansions, some of which were too small or otherwise undetectable by flow 
cytometry Vbeta analysis. This could be related to the activating effects of different 
STAT3 mutations, but also to other factors causing changes in proliferation potency or 
apoptosis rate of expanded cells. First, these could be additional lymphocyte survival-
affecting somatic mutations such as those variants that were seen in patient exomes 
sequenced in studies I and III. Second, genome-wide association studies have 
revealed predisposing host factors in LGL leukemia-related autoimmune disorders, 
which could affect the proliferation potency also in LGL leukemia. For example, 
single nucleotide polymorphisms (SNP) near IL6ST and IL2RA loci have been 
reported to associate with higher risk to develop RA.238 The HLA-DR4 haplotype is 
connected to both Felty’s syndrome and LGL leukemia, and a polymorphism in 
MICA, which is an MHC class I-related gene, is associated with higher risk of 
developing LGL leukemia. 32 Thirdly, immune system dysregulation could play a 
role: the activated IL6-STAT3 loop and suppression of SOCS3 expression are seen in 
LGL leukemia patients independent of the STAT3 mutation status.4,234 Lastly, 
changes in the antigenic background, developing T cell anergy or exhaustion, and 
immunosuppressive therapy could activate or deactivate multiple clones with variable 
intensity.72 
 
STAT3 and STAT5B mutations discovered in LGL leukemia are clinically relevant. 
STAT3 mutations can be used as molecular markers at diagnosis, along with other 
already established factors, and they could prove useful during follow-up of treatment 
responses. The prevalence of STAT5B mutations is lower, but they could be specific 
markers to the rare CD56+ T-LGL leukemia. In study IV, the screening of STAT3 
mutations in lymphocyte subpopulations showed that in the two cases analyzed, 
methotrexate did not eradicate the mutated clones and the partial responses seen were 
probably due to the MTX-caused immunosuppression of cytotoxic lymphocytes. 
Cyclophosphamide induced better responses, which were connected to the 
disappearance of mutated clones during treatment. Large prospective trials concerning 
the treatment of LGL leukemia have not been done, but the ORR for methotrexate is 
approximately 50% and relapses are common, whereas for cyclophosphamide ORR is 
70% and relapses or failures are more uncommon.12,53,55  
 
STAT3 activation is common in malignancies and autoimmune disorders, and 
consequently it presents a potential and attractive therapeutic target in multiple 
previously uncured disorders. LGL leukemia with activating STAT3 mutations would 
be interesting platform to study the effects of different STAT3 inhibitors. Small 
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molecule SH2 domain inhibitors have shown promise in preclinical trials, their 
mechanism being the disruption of the SH2-phosphotyrosine interaction. Tested 
compounds such as BP-1-102 and OPB-3112 have both shown efficacy in tumor-
specific growth inhibition.239,240 DNA binding domain-targeting decoy 
oligonucleotides block the nuclear transportation of STAT3, but their specificity and 
penetrance to different tissues could be a problem.241 STAT3 mutations could affect 
the binding of small molecule SH2-inhibitors, but the small-molecule STAT3 
inhibitor STA-21 suppressed the growth of two STAT3-mutated cell lines.212 
Similarly, STA-21 induced apoptosis of LGL leukemia patient-derived CD8+ T cells 
independent of the STAT3-mutation status, but treatment with JAK1/2-inhibitor 
ruxolitinib did not have remarkable effect on leukemic LGLs.242 OPB-3112 is 
currently in phase I/II clinical trials, but no results have been published to date. 
Although the prevalence of STAT5B mutations was lower in LGL leukemia, STAT5 
could be an appropriate therapeutic target, especially in aggressive CD56+ T/NK-
LGL if N642H mutations are truly the ultimate drivers of this rare disease. Small 
molecule SH2-domain inhibitors are being developed in preclinical trials for 
treatment of STAT5-related cancer such as CML.243,244 One interesting compound is 
pimozide, which is an antipsychotic drug, and already in clinical use. It induces 
apoptosis of BCR-ABL1-positive CML cells and FMS-like tyrosine kinase-3 (FLT3)-
mutated AML-cells through STAT5 inhibition, but the mechanism is unknown.  
 
The discovery of activating STAT3 and STAT5B mutations provides a novel 
molecular basis for LGL leukemia and has provided new information about the clonal 
landscape and clonal evolution during the course of the disease. These observations 
support the theory of a common pathogenesis for T-LGL leukemia and CLPD-NK. 
Furthermore, the discovery of STAT3 mutations in patients with concomitant 
autoimmune disorder or bone marrow failure and LGL leukemia may indicate that 
acquired genomic changes also underlie a proportion of autoimmune diseases, and 
these disorders can result from chronic antigen exposure in combination with 
immunogenetic factors such as STAT mutations. Finally, STAT3 mutations present a 
novel therapeutic target and STAT3 inhibition may improve the treatment results of 
LGL leukemia. 
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Figure 40. Hypothesis of LGL leukemia pathogenesis. An exposure to an unknown 
antigen (such as microbial antigen) may lead to the initial oligoclonal expansion of 
cytotoxic lymphocytes, some of which could have a T cell receptor cross reacting with 
autoantigens. Predisposing immunogenic factors lead to the failure in restraining the 
immune response. Persistent autoantigen stimulation and inflammation induces the 
activation of JAK-STAT pathway, increasing the rate of mutagenesis in STAT genes. 
Gain-of-function STAT3 and STAT5B mutations give growth advantage to the 
mutated lymphocyte clones, and facilitate the development of LGL leukemia. A 
substantial proportion of LGL leukemia patients harbor multiple STAT3-mutated 
lymphocyte clones. The events shaping the clonal landscape include both stimulatory 
and inhibitory factors: STAT3 and STAT5B mutations have different functional 
properties, and their potential to drive leukemic LGLs is different. A new antigen 
exposure can give rise to new lymphocyte clones. Inhibitory factors suppressing 
leukemic LGLs include immunosuppressive treatment and T cell exhaustion. 
Depending on the antigen target of leukemic LGLs, symptoms include cytopenias and 
autoimmune manifestations, which are caused by the cytotoxicity of leukemic LGLs. 
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CONCLUSIONS  
This thesis provides new information about the molecular pathogenesis of LGL 
leukemia. Exome sequencing of a T-LGL leukemia patient led to the discovery of a 
STAT3 SH2 domain mutation D661V, and subsequent screening revealed a 
prevalence of STAT3 mutations of 40% in T-LGL leukemia and 30% in CLPD-NK 
patients. The mutations were activating both in vivo and in vitro. The patients who 
carried STAT3 mutations were more often neutropenic and had rheumatoid arthritis, 
suggesting that mutated cells could have more potent cytotoxicity. The dysregulation 
of anti-apoptotic and pro-survival pathways and gene expression patterns were similar 
in different LGL leukemia patients, independent of the mutation status, which 
supports the notion of universal STAT3 activation also in  STAT3-unmutated LGL 
leukemia patients and suggests that other mutations in JAK-STAT3-axis may also 
exist and drive leukemic LGLs.  
 
The screening of STAT3 mutations by deep amplicon sequencing revealed 
multiple STAT3 mutations in 20% of the mutated patients, and they existed mostly in 
different lymphocyte clones. The finding supports the model of a dynamic clonal 
landscape in LGL leukemia in which T cell exhaustion, different functional properties 
of STAT3 mutations, other immunogenetic factors, therapies given, and dysregulated 
immune system all affect the clonal LGL population, giving rise to new clones while 
others are suppressed. The analysis of the TCRB CDR3 region by deep sequencing 
did not suggest a common antigen target between multiple clones of a same patient or 
in a comparison of the TCRB CDR3 repertoire between the T-LGL leukemia patients 
analyzed. However, this does not exclude the existence of a common antigen behind 
LGL leukemia expansion. STAT3 mutations are seen in patients suffering from 
rheumatoid arthritis and different bone marrow failure syndromes, with or without 
concomitant LGL leukemia. One theory is that after a pathogen exposure, 
crossreactivity of antigen epitopes leads to the expansion of self-targeting 
lymphocytes, which acquire somatic mutation resulting in development of LGL 
leukemia with concomitant autoimmunity or bone marrow failure. Mutations in 
STAT3 were also clinically relevant: complete remission during immunosuppressive 
therapy was connected to the eradication of leukemic STAT3-mutated clone. 
 
The genetic landscape of STAT3-unmutated patients is still mostly undiscovered, 
but a small proportion of these patients carried similar activating mutations in 
STAT5B gene. One of these mutations, N642H, was connected to rare atypically 
aggressive CD56+ T-LGL leukemia, and could present a driver for the disease.  
 
To conclude, activating STAT3 and STAT5B mutations are novel, highly specific 
molecular markers for LGL leukemia. The mutations can be used as diagnostic tools 
alongside the other established clinical and hematological parameters, and they also 
prove the clonality in the case of CLPD-NK. STAT3-targeted therapies could be used 
in future to treat LGL leukemia. Further studies are warranted to understand the 
antigen targets initiating LGL leukemia expansion, the lymphocyte population where 
STAT3/STAT5B mutations occur, the reason for the frequent loss of self-tolerance in 
LGL leukemia, and also the transcriptional targets of mutated STAT3/STAT5B and the 
effects they have on the signaling pathways of leukemic LGL.  
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